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INTRODUCTION 
Diabetes Mellitus is a group of metabolic disorders with different subtypes 
of diabetes with hyperglycemia Regardless of its etiopathology, diabetes 
progresses through several clinical stages. It may present with characteristic 
symptoms or individuals may remain asymptomatic for a very long 
time.Consequently, diabetes is often diagnosed by an abnormal routine 
blood test by then some complication has already set in. 
Diabetes mellitus is a group of metabolic disease. It is due to insulin 
secretary defect and insulin action or both. Dysfunction or organ failure 
occurs with hyperglycemia. Organs affected are kidney, nerves, eyes, heart 
and blood vessels, skin. 
CLASSIFICATION 
Two types: 
Type 1 Diabetes – lack of insulin secretion. 
In Honeymoon remission phase patient will return to normoglycemia even 
after ketoacidosis. It may require insulin. Eg: type 1 diabetes mellitus occur 
in pregnancy period. 
Type 2 Diabetes – due to resistant to insulin and insulin secretory defect. 
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Diabetes develops with congenital defect in beta cell function, congenital 
defect in insulin action, exocrine pancreas defect. Depends upon the disease 
process, the degree of hyperglycemia varies. 
ETIOLOGICAL CLASSIFICATION OF DIABETES 
1. Diabetes mellitus Type 1 
a. Immunologically related 
b. Unknown cause 
2. Type 2 diabetes mellitus 
3. Other specific types 
a. Genetically mediated defects in function of Beta cells-MODY type 1 
to type 6 mitochondrial diabetes 
b. Genetically mediated defects in action of insulin – Insulin resistance 
type A 
c. Lipoatrophic diabetes 
d. Pancreatic disease 
(i) Fibro calcific pancreatitis 
(ii) Pancreatectomy 
(iii) Cystic fibrosis 
e. Endocrinopathis 
(i) Acromegaly 
(ii) Cushing’s syndrome 
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(iii) Phaeochromocytoma 
(iv) Hyperthyroidism 
f. Drug induced  
Glucocorticoids 
           Thyroid hormone 
Diazoxide 
Thizides 
Dilantine 
Vacor,pentamidine, olanzepine,rifampicin 
g. Infections  
Congenital Rubella 
                   Cytomegalovirus 
                    Mumps 
h. Uncommon forms of diabetes  
      “stiff-man” syndrome -Due to antibodies against insulin receptor 
i. Genetic syndrome association  
Down’s syndrome 
                   Turner’s syndrome 
                   Klienfelter’s syndrome 
                   Myotonic dystrophy 
                   Praderwilli syndrome. 
4. Gestational diabetes 
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PATHOGENESIS 
TYPE 1 DIABETES MELLITUS 
               Type 1 diabetes is of autoimmune origin and is related to a genetic 
– environmental interaction of human leukocyte antigen genes with an 
unknown environmental trigger which could vary from viruses to cow’s 
milk protein. Autoimmune islet cell destruction occurs which leads to 
release of antigens and the production of multiple antibodies as an 
epiphenomenon which are in fact detectable prior to the onset of diabetes in 
greater quantities and decline in titer after several years of diabetes have 
transpired.The genetic component of Type 1 diabetes is stronger than that of 
type 2 diabetes contrary to that of traditional thinking. 
Genetic Factors 
Type 1A diabetes is due to multiple gene polymorphisms. In genes, 
apart from major histocompatibility complex (MHC), larger effect is due to 
HLA alleles; followed by insulin gene polymorphism and lymphocytes 
specific tyrosine phosphate.HLA DR3 & DR4 is present in most of type 1 
Diabetes mellitus. Other candidate genes include CTLA-4.IL2RA, SH2B3, 
etc. 
 
Autoimmunity 
Initiation and progression of autoimmune diabetes mellitus is due to 
auto antigen is present in pancreatic Beta cell. These auto antigens include 
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insulin, Glutamic-acid decarboxylase(GAD), insulinoma-associated protein 
2 and the autoantigens is znT8, a zinc transporter of islet beta cells. In 
initiation of injury, exact initiating auto antigen is not known. The 
autoimmune response in type 1 diabetes affect other organs like thyroid, 
adrenal, tissue tranglutaminase (celiac disease).There  is also an increased 
evidence of cell mediated immunity. 
Environmental Factors 
Virus infections affect Beta cells by initiating autoimmunity. The 
candidate viruses are Coxsackie and certain enteroviruses. Diet is also 
important factor for development of T1 diabetes mellitus. Those are albumin 
in cow’s milk, most of infant formulas. 
TYPE 2 DIABETES MELLITUS 
Type 2 diabetes is classified as a “complex disease”. It is a disorder of 
polygenetic in origin and is strongly influenced by environment factors (in 
contrast to thalassemia which is a “simple” disease that has a genetic origin 
not influenced too much by environmental factors).Type 2 diabetes was 
traditionally marked as a disease precipitated largely by insulin resistance 
due to weight gain and lack of physical activity.However most recent 
research indicates that it is of multifactorial origin. 
 
 
 
6 
 
Genetic Factors 
New diabetes susceptibility loci are identified by Genomic analysis. 
Various genes involved in pancreatic development, beta cell function, 
insulin synthesis, insulin release and action and these are found to be 
associated with increased risk of type 2 diabetes.The one gene which seems 
to be important in several populations for an early secretory defect right 
across the board is Transcription factor 7 like (TCF7L2) which regulates 
beta cell survival and function. Transcription factors that contain high 
mobility domains it binds to Beta carotenin & activate receptors, this 
complex initiate expression of target genes. 
KCNJ11: Sulfonylurea receptor is down streamed by islet ATP - sensitive 
gene potassium channel.Spans 1 kb and is located directly downstream of 
the gene encoding the Sulfonylurea receptor.Adipocyte differentiation is by 
transcription factor, PPAR gamma 2, the gene that encodes the peroxisome 
proliferator – activated receptor, itself a target for medications that lower 
insulin resistance: the P12A polymorphism in PPAR gamma had been 
conclusively associated with common type 2 diabetes.Other candidate genes 
– beta 3- adrenergic receptor, calpain 10, HNF1 beta and IGF2BP2 are the 
genes found to be associated with type 2 diabetes. Type 2 Diabetes mellitus 
is also associated with polymorphism candidate genes. 
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Environmental Factors 
Lifestyle   
The major precipitating factor is environmental which encompasses 
diet and sedentary lifestyle. Ironically , high calorie dense foodstuffs may 
actually cost less when compared to healthy food items like fruits and green 
vegetables.The lack of physical activity is due to improved forms of 
motorized transport,escalators and elevators; professions which entail little 
physical activity and encourage a sedentary such as in the software industry 
and other similar jobs. Communication facilities like mobile telephony; 
entertainment facilities like television and computer/video games are now 
available at a low cost. All in all, enormous lifestyle changes have occurred 
in the last three decades even in developing countries increasing the 
propensity of the problem. 
Role of obesity and inflammation  
Obesity is the cause for peripheral resistance to insulin. It decreases 
sensitivity of Beta cells to glucose. It decreases insulin mediated glucose 
uptake. Weight loss reduces blood sugar level.  
Inflammation is mediator to obesity, Diabetes and atherosclerosis. Type 2 
Diabetes Mellitus is also associated with increased levels of C reactive 
proteins, IL-6, PAN-1 & WBC. Adipokines are responsible for 
inflammatory activity which are released by adipokines .These adipokines 
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include leptin, adipocytes, tumor necrosis factor, resistin, obestatin, 
upcoupling protein -2 and retinol binding protein - 4 
Role of intrauterine development  
The relationship between birth weight and subsequent risk of type 2 
diabetes is U shaped. Both low and high birth weight are associated with 
increased risk of type 2 diabetes in adulthood, though this is well proven 
with low birth weight. Increased risk of type 2 Diabetes mellitus associated 
with higher birth weight and premature babies. Low birth weight, by 
multiple mechanisms may lead to a greater propensity for diabetes mellitus 
later in life which include insulin resistance as well as insulin secretory 
defect.This could be due to increased peripheral insulin resistance, 
especially in muscles and reduced hepatic insulin sensitivity. Additionally 
defects in GLUT-4 and insulin secretion have been identified in those born 
low birth weight. A secretory defect in the beta cell may be present from a 
fairly early point of time in life.Increased risk of diabetes is associated with 
higher birth weight (>4.0 kg). Children born prematurely, irrespective of 
their birth weight, may be at increased risk for type 2 diabetes and other 
disease of adulthood associated with insulin resistance. 
 
DIAGNOSIS OF DIABETES MELLITUS 
Blood glucose is the important for diagnosis of diabetes mellitus. Three 
ways to diagnose diabetes are possible, and subsequent days random blood 
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sugar level is to be seen.75 gm OGTT is more sensitive and rarely 
performed. Because of its ease, patientsacceptability and lower cost, 
measurement of fasting plasma glucose is the preferred diagnostic test.  
Impaired fasting glucose    -Fasting glucose 100 – 125mg/dl 
Impaired glucose tolerance - 2 hour post-load/postprandial glucose 140-199 
mg/dl 
CRITERIA FOR THE DIAGNOSIS OF DIABETES MELLITUS 
Symptoms of hyperglycaemia and a causal plasma glucose > equal to 200 
mg/dl. Casual is defined as any time of day without regard to time since last 
meal. The classic symptoms of hyperglycemia include polyuria, polydipsia 
and unexplained weight loss. 
                                                                    (Or) 
Fasting >equal to 126 mg/dl. Fasting is defined as no caloric intake for at 
least 8 hours. 
                                                                    (Or) 
2-h plasma glucose > equal to 200 mg/dl during an OGTT or postprandial. 
The test should be performed as described by the WHO, using a glucose 
load containing the equivalent of 75 g anhydrous glucose dissolved in water. 
This is the basis of the definition of fasting plasma glucose levels being 
more than 126mg/dl as a defining point in diabetes.                                                                                                                             
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EPIDEMIOLOGY OF DIABETES MELLITUS 
TYPE 1 DIABETES MELLITUS 
            Type 1 diabetes previously called insulin-dependent or juvenile 
diabetes. It is caused by destruction of beta cells. It is mediated through 
immune mechanism, leads to lack of insulin secretion and insulin 
deficiency. Type 1a (autoimmune form) diabetes (T1aDM) is precede by a 
subclinical period of T-cell- mediated autoimmune destruction of beta cells. 
T- cell mediated beta cell destruction results in auto antibodies formation. In 
children it is usually rapid onset of symptoms and dependence on exogenous 
insulin for survival. 
NATURAL HISTORY OF TYPE 1a DIABETES 
The natural history of type 1a DM includes four distinct stages: 
1. Autoimmunity to Beta cells with insulin secretory defect. 
2. Appearance of clinical diabetes 
3. Transient recovery 
4. Once diabetes is established it leads to acute and chronic 
complications and death in premature. 
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Preclinical Beta Cell Autoimmunity 
Type 1a DM is due to autoimmune destruction of Beta cells in 
genetically susceptible host to environment. Antibodies against specific beta 
cell antigens, such as glutamic acid decarboxylase (GAD) or ICA512. 
Family History 
The prevalence in first degree relatives of type 1 diabetic persons is 
increased 3-5 times, compared to that in school children with no family 
history of T1DM. The risk of T1DM among the relatives is 20 times higher 
than in the general population. 
Candidate Genes 
The HLA-DR2, protects type 1 Diabetes Mellitus. it is found in about 
15% of GAD and young relatives of IAA positive patients. However, over 
90% of those strongly and/or persistently ICA positive are HLA-DR3 or 4, 
similar to T1DM patients. 
ENVIRONMENTAL FACTORS 
Viruses 
Viral infections instigate autoimmunity. Two infections with similar 
viruses are responsible for type 1 diabetes mellitus. Viruses are mumps, 
rubella, measles, chickenpox, coxsackie, ECHO4 and rotavirus infection. 
Newborns and infants are particularly likely to develop a persistent infection 
and among patients with congenital rubella syndrome, 70% have ICAs. 
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P2-C protein of coxsackie virus and the GAD protein may be responsible 
for autoimmunity. 
Dietary Factors 
The intestinal barrier is compromised when it is exposed to cow’s 
milk bovine serum or beta casein. It is the important cause for 
autoimmunity. 
The association between cow’s milk and autoimmunity could be due to the 
effect of beta – casein immune stimulating hexapeptide. It is present in Bos 
Taurus cows. 
CLINICAL ONSET OF T1DM 
25-45% of Type 1 DM patients are younger than 20 years. Severe 
manifestations occur with DR4 allele, younger age, female gender, no 
family history, lower socio economic status. If 90% of islets are destructed, 
type 1 DM will present as severe manifestations. In the age of 7- 14 years, 
60% of beta cells are destructed. If the age of patients is more than 14 years, 
the beta cell destruction is 40%.  
Symptoms of diabetes mellitus polyuria, polydipsia, and weight loss 3-5 
weeks prior to diagnosis. 
Age 
Due to alteration in infection pattern and increase in insulin 
resistance, type 1 diabetes mellitus peaks at 2yrs, 3-5yrs, 9 – 15 yrs. 
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Gender 
T1DM occurs equally in males and females. Peak incidence in 
females is 1-2 years earlier than males. 
Viruses 
Herpesviruses, mumps, rubella, and retroviruses have been 
implicated. There is also increasing incidence of T1DM in patients with 
congenital rubella syndrome. In T1DM, congenital rubella syndrome is also 
responsible. In postnatal, rubella exposure to the MMR vaccine causes 
T1DM. The incubation period of T1DM in CRS patients is 6-21 years.No 
increase in risk of diabetes or pre diabetic autoimmunity with routine 
childhood immunization. 
DIETARY FACTORS 
There is also association between T1DM and nitrates and nitrites 
present in water. 
REMISSION (“HONEYMOON PERIOD”) 
Those who are presenting in older age and less severe initial 
presentation, and low or absent ICA or IA are associated with deeper and 
longer remission. Younger children those who are having HLA DR3, DR4, 
phenotype leads to destruction of beta cell occur within 3 years of diagnosis. 
In older patients it is slower and partial. In 18% of patients, function of beta 
cell is preserved even 10yrs after diagnosis. 
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COMPLICATIONS 
Acute complications of T1DM (diabetic ketoacidosis, low blood 
sugar, and infection.). For renal failure,vision loss, amputation, diabetes is 
the important cause.Other reasons are cardio vascular disease  and 
premature death. 
TYPE 2 DIABETES MELLITUS 
Type 2 diabetes mellitus, is otherwise called as non – insulin 
dependent diabetes. The prevalence of the disease is still rising worldwide. 
RISK FACTORS 
Familial Aggregation 
Risk is increased two- to five fold if a parent or sibling has the 
disease. 
Genes 
Genes responsible for T2DM is identified only in small 
number.T2DM is genetically complex disease. Putative susceptibility genes 
are identified by Genomic scans. Genomic scans identify the locus or loci 
which are in chromosome. Genes vary from population to population. 
Obesity 
          Obesity is one of the components of T2DM. It is the most important 
predictor in disease process. In non obese persons, it is low in incidence. 
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Physical Activity 
           Many studies indicate the important role of physical activity in the 
development of T2DM. Reduced physical activity patients have high BMI, 
high BP. 
GESTATIONAL DIABETES 
             In T2DM, gestational diabetes (diabetes first recognized during 
pregnancy) is the important risk factor in women. 
OTHER RISK FACTORS 
Reduced birth weight 
Intrauterine diabetic environment 
Exposure to metabolic environment. 
Low Birth Weight 
   Reduction in Beta cell mass is due to nutritional deprivation. This is 
due to “thrifty phenotype”. It is an acquired defect expressed as T2DM.Low 
birth weight is also associated with systemic hypertension, insulin resistance 
and dyslipidemia.. There are certainly paternally derived genes that are 
linked to low birth weight. 
Intrauterine Environment 
The intrauterine environment increase the risk of T2DM.At early age 
itself, offspring of diabetic pregnancies develop T2DM.These patients 
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insulin secretary capacity is in reduced level. Diabetes development is 3 fold 
higher in patients those who are born to Diabetic mother. It is due to 
intrauterine programming. 
Inflammation 
Several markers are also associated with T2DM and its metabolic 
precursor, insulin resistance. Those are IL6,CRP,other cytokines, fibrinogen 
and plasma activator inhibitor – 1.The extent to which these proteins are 
involved in the pathogenesis of T2DM is not clear. 
Sex Hormones 
Reduced levels of sex hormones binding globulin leads to 
development of T2DM in females. Men with testosterone level and women 
with increased level of androgen are resistant to insulin. Insulin resistance, 
or hyperinsulinemia, and hyperandrogenemia and nulliparity are also 
characteristic of the polycystic ovarian syndrome. 
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REVIEW OF LITERATURE 
In the body largest organ is skin. It can be easily inspected for scientific 
purposes. Physical signs of diabetes is due to dysregulation of glucose, 
insulin, and lipids. NEG of cutaneous proteins is due to chronically elevated 
blood sugar. This leads to advanced glycation end products 
(AGEs).Chronically elevated blood sugar results in nonenzymatic 
glycosylation (NEG) of cutaneous proteins ,which leads to irreversible 
advanced glycation end-products (AGEs).AGEs have been proposed as the 
mechanism for thickened skin and scleroderma-like changes and limited 
joint mobility. Structural proteins, such as collagen, that have undergone 
NEG become insoluble and resistant to degradation. Certain AGEs are 
related to glycemic control whereas others change with age as well as with 
glycemic control. In intensive insulin therapy for patients in DCCT results 
in lower levels of skin collagen AGEs, reduction in HbA1C and reduction in 
microvascular complications. Normal activities of insulin and lipoprotein 
lipase are necessary for normal production and catabolism of certain plasma 
lipids particularly VLDLs. Diabetes is most common cause of severe 
hypertriglyceridemia. Individuals with insulin resistance and insufficient 
levels of insulin have high levels of serum triglycerides with cutaneous 
xanthomas. On the other hand, individuals with insulin resistance and 
hyperinsulinemia have clinical manifestations of acanthosis nigricans. There 
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are also profound changes in cutaneous structure and function based on 
abnormalities of nerves and blood vessels. Studies document that cutaneous 
sensory innervation is diminished in diabetes compared with controls. 
Nerves and neuropeptides are important for normal immune function and 
normal tissue repair. Poor tissue repair and infections contribute to skin 
ulcers. It has been documented that non healing ulcers are the frequent cause 
of amputation.   
Structural abnormalities of blood vessels include (1) increase in the 
overall thickness of the walls of the microvessels, (2) increased number of 
gaps between endothelial cells and pericytes in postcapillary venules, (3) 
homogenous basement membrane thickening between endothelial cells and 
pericytes of thermal micro vessels,(4) an increase in size and number of 
periadventitial fibroblast-like cells (veil cells).Functional abnormalities of 
the diabetic microvasculature include (1) increased permeability, increased 
baseline capillary pressure and decreased capillary peak blood flow 
following arterial occlusion, (2) normal resting blood flow to capillaries in 
dorsal fingers and toes, but a decreased response to heat induce 
hyperemia,(3) an increased resting cutaneous blood flow in the legs and the 
feet of diabetic patients with neuropathy but deficiency in the normal 
hyperemic response to heating. The defective hyperemic response was 
greater in the legs than arms and correlated with duration of diabetes, 
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retinopathy and proteinuria. Skin conditions that appear to be directly linked 
to endocrine, vascular, neurologic and immunologic impairment seen in 
diabetes mellitus. These conditions include ulcers, acanthosis nigricans, 
diabetic thick skin, cutaneous infections, cutaneous xanthomas. Number of 
the other clinical conditions pathobiology of disorders remains unclear. 
These include necrobiosis lipoidica, granuloma -annaulare, diabetic 
dermopathy, bullosis diabeticorum and acquired perforting dertomasis. 
Vasculopathy is a major factor in the pathogenesis of diabetic ulcers. The 
greatest risk factor for amputation in a study by Reiber and associates was 
low cutaneous blood flow as measured by transcutaneous oxygen pressure. 
There was a 16 fold excess risk of amputation if the TcPo2 was below 20 
mm pg. The most important predictors of non healing were low TcPO2 and 
high TcCo2 in the skin adjacent to the ulcers. 
Sensory neuropathy is also a major factor associated with diabetic 
ulcers and lower extremity amputation. Prevalence of symptomatic sensory 
neuropathy is 30 – 40% in diabetic patients compared to about 10% in the 
non diabetic population. Diabetic patients lacking vibratory sensation had a 
15.5- fold excess risk of amputation compared to diabetic patients with 
intact vibratory sense. Clinical examination and the use of a 5.07 Semmes-
Weinstein filament was the most sensitive test in identifying patients at risk 
for foot ulceration. Neuropathy and limited joint mobility was found to be 
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the most important etiologic factor for foot ulcers occurring on high 
pressure areas of patients with diabetes. Unperceived trauma such as blisters 
and ingrown toenails also relate in part to diminished influences of 
neuropeptides on skin immunity and tissue repair. Ulcers heal very slowly 
in diabetic patients with neuropathy. 
Management of lower extremity ulcers requires if stasis dermatitis is 
present, it should be treated with topical steroids on the skin adjacent to the 
ulcers. Edema control is essential. Peripheral edema was a significant causal 
factor in the pathway leading to lower extremity ulceration.TcPo2 may 
improve significantly when leg edema is treated by bed rest, leg elevation, 
sodium restriction, or appropriately used diuretics. Unna boots, ache wraps, 
compression stockings, and even contact casting may be useful. If severe 
arterial insufficiency occurs it does not preclude these interventions. 
Treatment of underlying local soft tissue infection is important. 
15% of diabetic patients with lower extremity ulcers develop 
osteomyelitis. Osteomyelitis should be suspected in deep or chronically 
draining ulcers, particularly if bone is exposed.  Diabetic patients with 
suspected osteomyelitis from a foot ulcer might receive a 10 week course of 
culture guided antibiotics followed by surgical debridement. Mechanical 
protection for neuropathic extremities is another key element in therapy of 
diabetic ulcer. 
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          Trials of growth- promoting factors and skin equivalents have been 
under investigation to enhance diabetic ulcers healing. New technologies for 
the topical treatment of diabetic treatment of diabetic foot ulcers show 
“modest benefit” if used with adequate off loading, debridement, and 
control of infection. LoGerfo and associates advocate the expanded role of 
arterial reconstruction for severe diabetic ulceration and gangrene, 
especially vein bypass graft to the dorsalis pedis artery. Prevention is by  
1. Daily foot inspection, particularly for neuropathic patients. Advise careful 
selection of footwear that is not rigid or constricting in design or requiring a 
break-in period. Fitting shoes or socks were the most common reasons for 
foot ulcers. Advise patients to inspect shoes for foreign bodies before 
putting them on and to avoid walking barefoot. 
2. Early health care attention for calluses, blisters, ingrown toe nails, dermatitis 
or athlete’s foot. 
3. Personally inspect the feet of diabetic patients at each visit. 
4. Advice patients with a history of ulceration that they are at high risk for re 
ulceration (34% at 1 year, 61% at 3 years and 70% at 5 years.) 
ACANTHOSIS NIGRICANS 
              Acanthosis Nigricans (NA) is a skin disorder that is a marker of 
hyperinsulinemia and insulin resistance. The clinical features include a 
velvety, warty hyperkeratosis which is black or grey brown in color, 
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observed on the back, and the sides of the neck. axillae, anogenital region 
and  other skin fold. The neck is the most consistency affected area, and it is 
also the most reliable area for quantification of AN. 
            The Prevalence of type 2 diabetes mellitus in this subpopulation of 
Native Americans with AN is 50% in individuals above the age of 40. AN 
has also been shown to be a risk factor for development of T2DM. AN is 
strongly correlated with hyperinsulinemia. It has been demonstrated to be 
independent risk factor for the development of ischemic heart disease. AN 
used as an inexpensive surrogate marker for hyperinsulinemia to identify 
children and adolescents with a future risk of T2DM and ischemic 
cardiovascular disease. Mechanism for Acanthosis Nigricans (AN) is due to 
excess binding of insulin to insulin like growth factor receptors and 
androgens excess. DNA synthesis and cell proliferation in vitro through the 
IGF-1 receptors in fibroblast is by high concentration of insulin. 
               Certain drugs such as nicotinic acid and diethyl-stilbestrol have 
been reported to cause AN. Treatment for AN is generally ineffective, 
although disappearance of AN has been observed in obese individuals with 
weight reduction to IBW and with discontinuation of offending drugs. 
DIABETIC THICK SKIN 
           Diabetes generally has thicker skin than their non diabetic 
counterparts. Collier and colleagues used ultrasound measurements to show 
that flexor forearm and medial upper arm skin in patients with diabetes 
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(mean age 25) was thicker than in controls. Diabetic patients with disease 
duration greater than 10 years and those with LJM of the hand had the 
greatest mean skin thickness. 
            SLS in children and young adults with type 1 diabetes mellitus is 
otherwise called as “diabetic hand syndrome”, limited joint mobility or 
“cherioarthropathy”. By palpation, thickening and induration of skin on 
dorsal fingers may be demonstrated. SLS and LJM typically begin on the 
fifth finger and progress radially, as well as from distal to proximal. With 
increasing duration of diabetes, the changes may be seen proximal to the 
metacarpophalangeal joint. 
            LJM is thought to result from deposition of connective tissue in the 
periarticular soft tissues around the joint capsule rather than being the result 
of a true arthropathy. Criteria have been defined for staging the severity of 
LJM and quantitating restrictions in motion with a goniometer. 
           Approximately 50% of adolescent patients with T1DM for more than 
5 years are affected. Adults with T2DM may be affected as well. Patients 
with T1DM, correlation was found between LJM or SLS and duration of 
DM. LJM or SLS correlated with retinopathy. Other sign of micro vascular 
complications have been reported to be associated with LJM or SLS 
retinopathy appears to be the strongest association. In a recent cross – 
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sectional study, 83 patients with LJM and T2DM were compared with 56 
diabetic patients without LJM for evidence of diabetic complications.  
            Cerebro vascular disease is 4 times common with LJM. Nephropathy 
is 3.3 times common. Coronary heart disease is 3 times common in patients 
of LJM. Longitudinal control of diabetes as measured by HbA1C was 
strongly associated with the presence or absence of LJM. 
            Pathogenesis of this condition is controversial evidence for the role 
of non enzymatic glycosylation of connective tissue is becoming stronger. 
Advanced glycation end products (AGEs) extracted from skin correlated 
significantly with signs of LJM in two studies. The most compelling data 
come from a longitudinal prospective study showing a two to three fold 
excess risk of LJM with HbA1C levels above 8% over a 2 year period. For 
every 1% increase in HbA1C level there was a 2.5 fold excess risk of LJM. 
Intensive insulin therapy may be beneficial in the treatment of LJM and 
SLS. 
               The reduction in skin AGEs suggests the effect of intensive insulin 
therapy may be beneficial. Physical therapy to preserve range of motion 
should be considered. Intensive insulin therapy in 122 patients in the DCCT 
resulted in lower levels of skin collagen AGEs. 
                Scleredema is usually described as a rare complication of 
Diabetes. In two studies the prevalence was reported to be 2.5% of 484 
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diabetic outpatients in a Veteran Administration Medical center in the 
United States and 14% of 100 hospital based diabetic patients at Kuwait 
University in Kuwait. Scleredema in diabetic patients is characterizes as 
firm non pitting edema of the skin, symmetrically distributed over the 
posterior neck, upper back and shoulders. It is asymptomatic, a fact that 
could lead to considerable under reporting of the phenomenon by both 
patients and physicians. A population based study would provide the best 
data regarding the true prevalence of scleredema of diabetes. 
               Scleredema of diabetes or scleredema diabeticorum is often 
reported as part of the spectrum of scleredema adultorum. It may be seen in 
both T1DM and T2DM, but much more common in type 2 disease. These 
type of scleredema are similar to the scleredema of diabetes in clinical 
appearance except they involve the face more often and may resolve 
spontaneously within 2 years. Monoclonalgammopathy and multiple 
myeloma have been reported with scleredema. 
                  The pathogenesis is unclear. Ohta and collaborators showed that 
serum from patients with scleredema and a paraproteinemia caused 
enhanced synthesis of extracellular macromolecules in cultured fibroblasts. 
Case reports regarding the use of electron beam radiation, penicillin, 
cyclosporine, both PUVA and prostaglandin E1 have recently been 
referenced. 
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CUTANEOUS INFECTIONS 
                  Modern metabolic management and antibiotic therapy, 
contributed to the view that the incidence of furunculosis, carbuncles, 
erysipelas and epidermophytosis is increased in diabetic patients. Infection 
clearly makes diabetes more difficult to manage and conversely 
hyperglycemia and ketoacidosis diminish chemotaxis, phagocytosis and 
bactericidal ability of white blood cells. It is difficult to correlate 
hyperglycemia with skin infections. 
                 Both a retrospective and a prospective population based study 
shown diabetes is the commonest risk factor for invasive group B 
streptococcal infection in adults in both responsible and prospective 
population based study. Skin and soft tissues were the most common local 
sites of infection. Approximately 30% of the cases occured in patients with 
diabetes and overall case mortality rate was 21-32%.Diabetes is also 
associated with a 3-7 fold increased relative risk of invasive group A 
streptococcal infections. 
             MEO is a pyogenic infection of the ear canal with pseudomonas 
aeruginosa which is characteristically seen in older diabetic patients with 
purulent discharge, facial swelling, unrelenting pain, hearing loss and 
granulation tissue in the ear canal. The mortality rate is cited as 20-40% 
despite appropriate antibiotics. 
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              Necrotizing fascitis is another uncommon but potentially lethal 
infection seen post operatively and following minor trauma as well as at 
injection sites. Organism may include facultative strepto-cocci, Bacteriodes, 
peptostreptococci and staphylococci. The perineum, trunk, abdomen and 
upper extremities are most commonly involved. Toxicity is often out of 
proportion to signs, Redness, induration, cyanosis and necrosis with 
overlying bullae may be seen. The most important aspects of treatment is 
early aggressive surgical debridement.An increased rate of cutaneous 
staphylococcal infection in a diabetic patients using continuous 
subcutaneous insulin infusion (CSII).Increase in the rate of staphylococcal 
carriage could not be demonstrated for patients using CSII compared with 
diabetic patients injecting insulin or normal control subjects. 
   Erythrasma is an infection of intertriginous skin with 
corynebacterium minutissimum. The organism produces a porphyrin 
pigment that results in characteristic coral red florescence when a wood’s 
lamp is shined on the skin. Bacterial infections may be treated with 
appropriate systemic antibiotics. Erythrasma may be treated with topical or 
oral erythromycin. 
             Candida albicans causes angular cheilitis, glossitis, vulvovaginitis, 
balanitis, finger web space infection and paronychia in diabetic patients. 
Candida infection is common in poorly controlled diabetes. Clinical 
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evidence of candida paronychia was observed in 9.6% of 250 diabetic 
women compared with only 3.4% of 500 nondiabetic women. Candida 
infections may be treated with oral or topical anti fungals. 
              The prevalence of toenail onychomycosis appears to be increased 
in patients with diabetes. The importance of treating dermatophyte 
infections on the feet of diabetic patients is that they may provide entry for 
subsequent bacterial infections. Topical antifungals usually suffice to 
control fungal infection on skin adjacent to affected nails, but oral agents are 
needed to clear the onychomycosis. 
               Mucormycosis is an infection caused by a ubiquitous fungal 
organism, found primarily in soil and decaying vegetation. It has been 
repeatedly reported in diabetic patients. Rhizopus and Mucor have been 
observed complicating skin ulcers on legs and hands in diabetic patients. A 
destructive nasal mucosa and sinus infection called rhino cerebral 
mucormycosis (RCM) is particularly devastating. Facial or ocular pain and 
nasal stuffiness is the easy manifestation. Amphotericin B and surgical 
debridement are the treatment of choice. Mortality rates for RCM have been 
reported to be 15-34%. 
ERUPTIVE XANTHOMAS 
            Diabetes is the most common cause of acquired 
hypertriglyceridemia. Triglyceride-rich chylomicrons are usually rapidly 
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cleared by the action of lipoproteins lipase. Lipoproteins lipase activity is 
decreased in uncontrolled diabetes. Insulin is necessary for normal clearance 
of plasma lipoproteins. Eruptive xanthomos may develop as the skin 
manifestations of chylomicrons in hypertriglyceridemic patients. Plasma 
lipoproteins can be shown to enter the skin, where they are phagocytosed by 
macrophages. These macrophages appear as foam cells in the eruptive 
xanthomas. 
            Eruptive xanthomas appear as 1 to 4 mm size most commonly 
present in extensor surface of arms, legs and buttocks. They appear as 
reddish yellow papules. They are usually asymptomatic, but these are the 
most important clinical signs because they may be the first indication of 
diabetes. The hypertriglyceridemia responds rapidly to diet and insulin 
therapy and the eruptive xanthomas usually resolve completely in 6-8 
weeks. 
NECROBIOSIS LIPOIDICA (NL) 
              The most recognized skin condition associated with diabetes is its 
taxonomy. The term necrobiosis lipoidica diabeticorum in 1932 generation 
of dermatologists and diabetologists have used the abbreviation “NLD” to 
refer to this condition. If one adds the term “diabeticorum” to search about 
80% of the published.  
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             NL was associated with diabetes in approximately two-thirds of 171 
cases reported from the Mayo clinic. Glucose tolerance tests performed on 
non diabetic patients revealed another 5-10% with abnormalities in 
carbohydrate metabolism. It is seen on scalp, fingers, hands, forearms, face, 
and nipple. It may be solitary. 
             The clinical presentation is usually the key to diagnosis but the 
histology is also characteristic. It is difficult to distinguish NL from other 
necrobiotic condition such as granuloma annulare. The histopathologic and 
immuno histochemical features of NL have been succinctly reviewed and 
contrasted with granuloma annulare (GA).The histological features of NL in 
middle to deep dermis are histiocytic granulomas with necrobiosis and 
periodic acid Schiff (PAS) positive staining. Nerve staining with s-100 is 
diminished in lesional skin and in the inflammatory perilesional areas. 
            The pathogenesis of NL remains unknown but many mechanisms 
have been proposed and reviewed. Proposed mechanism include hereditary, 
microangiopathy, increased production of fibronectin by endothelial cells, 
increased factor VIII related antigen, abnormal platelet function and 
prostaglandin synthesis, accelerated collagen aging and immune –mediated 
vasculopathy. 
          NL and GA are characterized by altered extracellular matrix and 
degenerative changes in collagen and elastic fibers. There is no evidence 
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that poor glycemic control is a factor in NL although this has not been 
extensively studied using newer techniques for subfractionating AGEs from 
skin biopsis.TcPo2 value are significantly lower in lesional skin than in 
adjacent normal skin. 
         The long list of treatments for NL is evidence that no treatment is the 
accepted standard of effective care. Experience with dipyridamol and 
aspirin has been disappointing. Treatment for early inflammatory phase of 
NL is high potency topical steroids. Perilesional skin is injected by injection 
triamcinolone, ulceration may occur with local steroids. Treatment is short 
term use of systemic steroids and pentoxifylline 400 mg three times a day. 
          The main issues for plaque type NL are the cosmetic appearance and 
protection to avoid ulceration. Cover-up products such as Derma blend or 
cover mark may be useful for special occasions to help cosmetically 
Protective padding is well advised for ulcer protection during high risk 
activities and a night light is useful to prevent inadvertent trauma when 
using the bathroom at night. 
         When ulcers occur in NL, the same principles apply as discussed 
above for diabetic ulcers. A report of the successful use of cyclosporine for 
the treatment of persistently ulcerated NL in two patients was published. 
Very large or recalcitrant ulcers in NL excision done. Split thickness skin 
grafting appears to be effective and the preferred therapy. 
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GRANULOMA ANNULARE (GA) 
          GA is a benign self-limited condition characterized by annular 
plaques usually seen over the dorsal hands, feet or ankles. The plaques often 
consist of a ring of papules, red to reddish purple in color, with clearing or 
flattening in the center. They may be solitary papules, nodules or plaques 
and on rare occasions presents as subcutaneous nodules or perforating 
lesions. About 15% of patients have more than 10 lesions and 7-10% has 
generalized lesions. The localized form tends to come on early in life and 
usually clears within 2 years, whereas in the generalized form the mean age 
of onset is 52 years and it rarely clears spontaneously. 
         The pathogenesis of GA remains unknown. Its association with 
diabetes has long been debated. Diabetes is present in 9.7% of 1353 patients 
with localized lesions of GA and 21% of 100 patients with generalized GA. 
In two more recent retrospective studies 11 of 61 patients (18%) and 10 0f 
84 patients (12%) with GA has diabetes. A large population based study of 
patients with DM, but the more recent data continue to support the 
arguments in favour of an association. 
          Treatment with high potency topical steroids or steroids injection may 
be effective for localized GA, but it is usually an asymptomatic self-limited 
process.GA may be more pruritic and persistent and it is certainly more 
cosmetically disabling. Encouraging results for generalized GA have been 
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reported with PUVA. The sunburn has been reported as a precipitating 
factor for some patients with generalized GA. Limited success has been 
reported with systemic corticosteroids, chloroquine, potassium iodide, 
sulfones, niacinamide and chloropropamide as reviewed. GA lesions have 
been reported in patients with HIV infection. If risk factors for HIV are 
present antibody testing should be considered. 
DIABETIC DERMOPATHY 
            Melin is generally credited with describing atrophic circumscribed 
lesions localized to the lower extremities in diabetic patients. They consist 
of small (2-10mm), rounded, brownish, atrophic lesions almost exclusively 
over the pretibial surface of the legs. They have subsequently been referred 
to most commonly as “shin spots” and diabetic dermopathy. Controversy 
has surrounded this condition regarding the prevalence, the specificity as a 
cutaneous marker for diabetes, the relationship to other complication of 
diabetes and its relationship to trauma. 
            Prevalence of atrophic shin spots ascertained from diabetic patients 
in outpatient clinics has ranged from 24-65% for males and 4-39% for 
females. The prevalence in non diabetic control groups was 7% of 104 
patients in a hypertension clinic, 20% of 183 patients in an endocrine clinic, 
3% of 100 patients in dermatology clinic and 1.6% of 201 healthy medical 
students.T1DM and 39% of patients with T2DM compared with 2% of a 
34 
 
control group comprised of 100 healthy people, mainly hospital personnel 
aged 15-50 years. Diabetic dermopathy does occur with greater frequency in 
patients with diabetes. There is an agreement that it occurs more frequently 
in men and the duration of diabetes is directly related to the prevalence of 
diabetic dermopathy. 
            The pathogenesis of this condition is unknown. Trauma has been the 
leading candidate even though most patients are unaware of associated 
trauma and the lesions are asymptomatic. Arguments in favor of trauma are 
supported by the location on the shins and increased prevalence in men. 
Melin was unable to produce lesions on the shins of diabetic patients with a 
rubber hammer and found no lesions on the shins of normal health soccer 
players. Linther was able to induce atrophic circumscribed skin lesions at 
the site of trauma from locally applied heat and cold in patients with 
diabetes. Diabetic dermopathy represents a pattern of repair in response to 
injury or inflammation within the milieu of diabetes. 
           Melin found an association of atrophic shin spots with other clinical 
complications of diabetes, including retinopathy, lower extremity vascular 
disease and nephropathy. Patients with DM a strong statistical relationship 
with retinopathy, nephropathy and neuropathy was reported. The histology 
is not diagnostic. It shows epidermal atrophy and pigment inclusion but no 
clear cut evidence for a vasculopathy in lesional skin by either histology or 
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electron microscopy. No treatment is necessary since it is without symptoms 
or morbidity. 
BULLOSIS DIABETICORUM 
           The abrupt onset of bullae on the extremities has been reported as a 
rare condition associated with diabetes. The lesions are usually on the toes, 
feet and distal lower extremities but also observed on the fingers, hands and 
forearms. They are unrelated to any apparent trauma or infection and heal 
without scarring in 2-5 weeks unless they become infected. The condition 
may resolve spontaneously it may recur over a number of years. 
           The histopathology is variable as reviewed by Toonstra. The level of 
separation resulting in the bulla may be intra epidermal or sub epidermal. 
The intra epidermal split may occur anywhere from supra basally to sub 
corneally, usually without acantholysis. Spongiosis may be present. Direct 
immuno florescence is usually negative. 
             The pathogenesis is unknown and the treatment is supportive wound 
care. The main significance of this condition is recognition. The differential 
diagnosis includes bullosis impetigo, bullous pemphigoid, pemphigus 
vulgaris, epidermolysis bullosa acquista, porphyria cutanea tarda (PCT), 
bullous erythema multiforme and insects bite reaction. A negative culture 
for staphylococci and negative direct immuno florescence on skin biopsy 
and compatible histopathology makes this diagnosis by exclusion. A 
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porphyrin screen could be considered if other signs of PCT are present. The 
diagnosis is important because the treatment of a number of the other 
blistering disease involves the use of systemic steroids or 
immunosuppressive therapy which confers significant risk of toxicity to 
diabetic patients. 
ACQUIRED PERFORATING DERMATOSIS 
            APD has been reported in association with diabetes and renal failure. 
Rapini and collaborators reviewed a variety of terms used for this group of 
conditions. They include Kyrli’s disease, relative perforating collagenosis 
(RPC), perforating folliculitis and ellastosis perforans serpiginosa. 
Histology may vary from location to location on the same patient and the 
pathogenesis is unclear. It appears more logical to consider these conditions 
together rather than to emphasize differences. 
             APD is characterized by trans epidermal elimination of what 
appears to be altered collagen. The clinical appearance consists of pruritic 
papules and nodules on the upper and lower extremities as well as the trunk 
and to a lesser extent the face. Diabetes with at least one complication 
(nephropathy, retinopathy, peripheral vascular disease or cardio myopathy), 
15 patients had nephropathy and 10 were on dialysis. Dialysis patients 
received prospective skin examination, 11% (8 of 72 patients) were 
observed to have APD. Seven of the eight patients had DM. 
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              These observations are supportive of the APD with DM and 
chronic renal failure, and it suggests that APD may be more common than 
previously appreciated. The pathogenesis is unclear, but treatment with 
glycemic control, ultraviolet light, retinoic acid or topical steroids may be 
effective. 
GLUCAGONOMA 
          Glucagonoma is one cause for diabetes that is potentially curable by 
surgery. This diagnosis should be considered in diabetic patients with 
calcitrant erosive dermatitis typically involving the central face, groin, 
friction areas and the distal extremities. It is usually seen in the clinical 
setting of weight loss, diarrhea, glossitis, anemia, hypo albuminemia and 
mild DM. Skin biopsy shows epidermal necrosis, edema and split in the 
upper spinous layer along with a neutrophilic infiltrate. The clinical and 
histologic features taken together resulted in the term necrolytic migratory 
erythema (NME). 
          Glucagonoma is a tumor of the alpha cells of the pancreas, which 
secrete glucagon. It is malignant in 60-80% of cases and often is metastatic 
at the time of diagnosis. The diagnosis is made more difficult by the fact 
that 15% of patients with glucagonoma do not have DM and some patients 
with NME have normal glucagon levels and no evidence of glucagonoma. 
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          The tumors can usually be visualized on CT scan. Selective celiac 
axis arteriography is the most useful diagnostic study for localizing the 
tumors and identifying metastases in the liver. Treatment usually includes 
surgical excision. Even in metastatic disease, cytoreductive surgery often 
results in long remission. Chemotheraphy may be helpful and long-acting 
somatostatin analogues results in good symptomatic relief even though they 
have no effect on tumor size. 
 SKIN COMPLICATIONS DUE TO INSULIN INJECTION 
           Intensive insulin therapy effectively delays the onset and slows the 
progression of micro vascular disease in T1DM. External insulin pumps are 
an effective alternative for intensive insulin therapy. Management of the 
skin complications of insulin therapy may become more problematic with 
intensive insulin therapy. 
            Lipoatrophy with less pure earlier insulin preparations was reported 
in 16% of patients, with highly purified insulin it occurred in 0-2.5% of 
cases. Lipohypertrophy has been attributed to local immune complex 
formation and complement fixation with release of lysosomal enzymes in 
response to a presumed antigenic component of the less purified insulin. 
CSII with regular HI and speculated that it is responsible for the 
improvement. 
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            Lipohypertrophy has not decreased with the use of highly purified 
insulin and HI. Lipohypertrophy was observed in 14% of patients using 
conventional insulin, 22% of patients injecting highly purified human 
insulin. It is thought that  it occurs because of a local anabolic effect of 
insulin that promotes fat and proteins synthesis. The problem can usually be 
alleviated by rotation of injection sites but the hypertrophic sites are often 
repeatedly used by the patients because they tend to be less painful. Patients 
should be discouraged from using the sites with lipohypertrophy because the 
insulin absorption can be delayed or inconsistent. 
         Local and systemic allergic reaction has been reported with insulin 
injection. A variety of factors may be involved including contaminating 
proteins, zinc and protamine as well as insulin itself. Such allergic reaction 
are usually IgE mediated although patients may have IgE antibodies to 
insulin without clinical evidence of an adverse reaction. IgE antibodies have 
been measured in sera from allergic non diabetic individuals with affinities 
and concentrations similar to those seen in diabetic patients. Local reactions 
to insulin are often transient and no major significance. They usually 
presents as a wheal and flare within 30 minutes. Systemic allergic reaction 
though rare they are potentially life threatening. They include urticarial, 
angioedema, anaphylaxis and the Arthus reaction. Highly purified insulin 
and HI are less immunogenic, allergic reactions are still observed. Intra 
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dermal testing may be used to find an insulin preparation to which the 
patients does not react. Desensitization techniques are useful for generalized 
insulin allergies. Systemic steroids and antihistamines are occasionally 
required. 
           Non immunologic cutaneous reactions have been reported to insulin 
injection as well. They include infections, zinc granulomas, sterile 
abscesses, silicon oil from disposable syringes and keloid formation as well 
as pigmentation that resemble acanthosis nigricans. 
         Continuous subcutaneous insulin infusion (CSII) deserves special 
mention because skin complications are the most common reason for the 
treatment discontinuation. Chatelau and collaborators reported on 116 
patients 14 cases of skin inflammation or infection during the study 
period.51% developed redness at the catheter sites, 19% developed 
subcutaneous nodules and 48% had whitish scars secondary to previous 
infections.  
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AIM OF STUDY 
 
To study the various Mucocutaneous Manifestations of type 1 and type 2 
Diabetes Mellitus 
To study its relation with glycemic status, age and duration of diabetes. 
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STUDY PROTOCOL 
PLACE OF STUDY: 
           Dermatology OPD, Dermatology ward, Diabetology OPD, medicine 
OPD and medicine ward in Stanley Medical College. 
DURATION: 
           March 2014 to September 2014. 
STUDY DESIGN: 
          Cross Sectional Study design. 
SAMPLE SIZE: 
          250 Patients with diabetes mellitus (type 1 and type 2). 
INCLUSION CRITERIA: 
          Patients with type 1 and type 2 Diabetes mellitus attending 
diabetology, dermatology and medicine OPD. 
EXCLUSION CRITERIA: 
              HIV 
            CKD 
            Malignancy 
            Known case of primary skin disorders 
            On immune suppressive drugs 
             Pregnant and lactating women 
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MATERIALS AND METHODS 
             Diabetic patients those who are attending Diabetology OPD, 
Dertmatology OPD, medicine OPD will be screened for dermatological 
manifestation. Patients glycemic status is evaluated with FBS, PPBS. 
Dermatologist opinion will be obtained. If needed, to confirm this 
pathological evaluation and further investigation will be done according to 
dermatologist advice. Patients mucocutaneous manifestation will be treated 
according to guidelines. 
ANALYSIS PLAN: 
            Data will be analysed with the SPSS software version 16.0for 
windows. All continuous data will be expressed as mean and SD and will be 
analysed using students test. Categorical data will be expressed as number 
(percentage) and analysed by chi square test. 
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OBSERVATION AND RESULTS 
Study Groups 
Treatment 
Groups Name of Group Study 
Number of 
Subjects 
Group A Good Control 
Mucocutaneous 
manifestation in diabetic 
study subjects with good 
blood glucose control(≤ 
180 mg/dl) 
 
26 
Group B Poor Control 
Mucocutaneous 
manifestation in diabetic 
study subjects with poor 
blood glucose control(> 
180 mg/dl) 
 
224 
 
Statistics  
Descriptive statistics was done for all data and suitable statistical tests of 
comparison were done. Continuous variables were analysed with Unpaired t 
test and categorical variables were analysed with the Chi-Square Test and 
Fisher Exact Test. Statistical significance was taken as P < 0.05. The data 
was analysed using EpiInfo software (7.1.0.6 version; Center for disease 
control, USA) and Microsoft Excel 2010. 
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Sample Size Calculation 
Sample size was determined on the basis of a pilot study in which the 
prevalence of cutaneous lesions in diabetics was measured at 20%.  We 
calculated a minimum sample size of 246 patients was required, assuming a 
type 1 error (two-tailed) of 0.05 and a margin of error of 10%. Therefore, 
the final sample selected was n=250. 
 
n= t² x p(1-p) 
  m² 
Description: 
n = required sample size 
t = confidence level at 95% (standard value of 1.96) 
p = estimated prevalence of malnutrition in the project area 
m = margin of error at 10% (standard value of 0.05) 
n= (1.96)² x 0.2(1-0.8) 
             (0.05)² 
n= 3.8146 x 0.16 
  
           0.0025 
= 246 
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Age 
Distribution 
All % 
Good 
Control 
% PoorControl % 
≤ 20 years 10 4 4 15.38 6 2.68 
21 to 40 
years 
48 19.2 9 34.62 39 17.41 
41 to 60 
years 
157 62.8 9 34.62 148 66.07 
> 60 years 35 14 4 15.38 31 13.84 
Total 250 100 26 100 224 100 
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Age Distribution All Good Control PoorControl 
N 250 26 224 
Mean 48.376 42.19231 49.09375 
SD 12.0165 17.08337 11.11478 
P value 
Unpaired t test 
0.54205296 
 
By conventional criteria the association between the study groups and age is 
considered to be not statistically significant since p > 0.05 
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Gender  
 
Gender 
Distribution 
All % 
Good 
Control 
% 
Poor 
Control 
% 
Male 111 44.4 7 26.92 104 46.43 
Female 139 55.6 19 73.08 120 53.57 
Total 250 100 26 100 224 100 
P value 
Chi squared Test 
0.58116 
 
By conventional criteria the association between the study groups and 
gender is considered to be not statistically significant since p > 0.05. 
Since age and gender is not statistically significant, it means that there is no 
difference between the groups. In other words the groups contain subjects 
with the same basic demographic characteristics. 
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Height  
 
Height 
Distribution 
All % 
Good 
Control 
% PoorControl % 
≤ 150 cms 16 6.4 6 23.07692 10 4.464286 
151 to 160 
cms 
111 44.4 10 38.46154 101 45.08929 
161 to 170 
cms 
82 32.8 8 30.76923 74 33.03571 
171 to 180 
cms 
41 16.4 2 7.692308 39 17.41071 
Total 250 100 26 100 224 100 
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Height 
Distribution 
All Good Control PoorControl 
N 250 26 224 
Mean 162.012 158.2308 162.4509 
SD 8.221083 9.052327 8.026151 
P value 
Unpaired t test 
0.30245622 
 
By conventional criteria the association between the study groups and 
height is considered to be not statistically significant since p > 0.05. 
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Weight 
 
 
Weight 
Distribution 
All % 
Good 
Control 
% PoorControl % 
≤ 50 kgs 16 6.4 5 19.23 11 4.91 
51 to 65 kgs 95 38 15 57.69 80 35.71 
66 to 80 kgs 133 53.2 5 19.23 128 57.14 
> 80 kgs 6 2.4 1 3.85 5 2.23 
Total 250 100 26 100 224 100 
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Weight 
Distribution 
All Good Control PoorControl 
N 250 26 224 
Mean 66.7 61.61538 67.29018 
SD 9.445787 9.670892 9.261555 
P value 
Unpaired t test 
0.7864537 
 
By conventional criteria the association between the study groups and 
weight is considered to be not statistically significant since p > 0.05. 
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BMI 
 
 
BMI 
Distribution 
All % 
Good 
Control 
% PoorControl % 
≤ 18.49 1 0.4 1 3.846154 0 0 
18.50 to 
24.99 
115 46 12 46.15385 103 45.98214 
25 to 29.99 111 44.4 9 34.61538 102 45.53571 
≥ 30 23 9.2 4 15.38462 19 8.482143 
Total 250 100 26 100 224 100 
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BMI Distribution All Good Control PoorControl 
N 250 26 224 
Mean 25.44934 24.95343 25.50691 
SD 3.145144 4.14922 3.013834 
P value 
Unpaired t test 
0.514461049 
 
By conventional criteria the association between the study groups and BMI 
is considered to be not statistically significant since p > 0.05. 
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Alcoholism  
 
Alcoholism All % 
Good 
Control 
% 
Poor 
Control 
% 
Alcoholism 
- 
223 89.2 25 96.15385 198 88.39286 
Alcoholism 
+ 
27 10.8 1 3.846154 26 11.60714 
Total 250 100 26 100 224 100 
P value 
Chi squared Test 
0.227479 
 
By conventional criteria the association between the study groups and 
alcoholism is considered to be not statistically significant since p > 0.05. 
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Smoking  
 
Alcoholism All % 
Good 
Control 
% 
Poor 
Control 
% 
Smoking - 210 84 25 96.15385 185 82.58929 
Smoking + 40 16 1 3.846154 39 17.41071 
Total 250 100 26 100 224 100 
P value 
Chi squared Test 
0.074122 
 
By conventional criteria the association between the study groups and 
smoking is considered to be not statistically significant since p > 0.05. 
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Systolic BP 
 
Systolic BP 
Distribution 
All % 
Good 
Control 
% PoorControl % 
≤ 120 mm hg 96 38.4 8 30.76923 88 39.28571 
121 to 130 mm 
hg 
69 27.6 9 34.61538 60 26.78571 
131 to 140 mm 
hg 
52 20.8 5 19.23077 47 20.98214 
141 to 150 mm 
hg 
33 13.2 4 15.38462 29 12.94643 
Total 250 100 26 100 224 100 
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Systolic BP 
Distribution 
All Good Control Poor Control 
N 250 26 224 
Mean 130.064 130.3846 130.0268 
SD 11.29221 11.55189 11.28749 
P value 
Unpaired t test 
0.88185124 
 
By conventional criteria the association between the study groups and 
systolic BP is considered to be not statistically significant since p > 0.05. 
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Diastolic BP 
 
Diastolic BP 
Distribution 
All % 
Good 
Control 
% PoorControl % 
≤ 70 mm hg 51 20.4 14 53.84615 37 16.51786 
71 to 80 mm 
hg 
129 51.6 6 23.07692 123 54.91071 
81 to 90 mm 
hg 
58 23.2 6 23.07692 52 23.21429 
91 to 100 
mm hg 
12 4.8 0 0 12 5.357143 
Total 250 100 26 100 224 100 
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Diastolic BP 
Distribution 
All Good Control Poor Control 
N 250 26 224 
Mean 80.84 76.53846 81.33929 
SD 8.550253 8.918434 8.384861 
P value 
Unpaired t test 
0.13797185 
 
By conventional criteria the association between the study groups and 
diastolic is considered to be not statistically significant since p > 0.05. 
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FBS 
 
 
Fasting BS 
Distribution 
All % 
Good 
Control 
% PoorControl % 
≤ 80 mg/dl 0 0 0 0 0 0 
81 to 110 
mg/dl 
18 7.2 17 65.38462 1 0.446429 
111 to 140 
mg/dl 
68 27.2 8 30.76923 60 26.78571 
> 140 mg/dl 164 65.6 1 3.846154 163 72.76786 
Total 250 100 26 100 224 100 
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Fasting BS 
Distribution 
All Good Control Poor Control 
N 250 26 224 
Mean 161.612 107.0769 167.942 
SD 42.87534 15.35428 40.48696 
P value 
Unpaired t test 
0.0000 
 
By conventional criteria the association between the study groups and 
fasting blood sugar levels among study subjects is considered to be 
statistically significant since p < 0.05.  
Statistical Significance 
This indicates that there is a true difference among groups and the 
difference is significant. . In simple terms, when studying the 
mucocutaneous lesions among diabetic patients, the fasting blood sugar 
levels in good blood glucose control group is predominantly 
less(107.07±15.35 mg/dl) when compared to poor blood glucose control 
group(167.94±40.49). It is statistically significant with a p-value of 0.0000 
according to unpaired t-test. 
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Clinical Significance 
 
The average fasting blood sugar levels in good blood glucose control group 
is meaningfully less than poor blood glucose control by 57% with a mean 
difference of 60.86 mg/dl between the groups. This difference is true and 
significant and has not occurred by chance. 
 
Conclusion  
We conclude that there is meaningfully real reduction in fasting blood 
glucose levels among good blood glucose control group  
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PPBS 
 
Post 
Prandial BS 
Distribution 
All % 
Good 
Control 
% PoorControl % 
≤ 120 mg/dl 2 0.8 2 7.692308 0 0 
121 to 140 
mg/dl 
1 0.4 1 3.846154 0 0 
141 to 200 
mg/dl 
23 9.2 23 88.46154 0 0 
> 200 mg/dl 224 89.6 0 0 224 100 
Total 250 100 26 100 224 100 
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Post Prandial BS 
Distribution 
All Good Control Poor Control 
N 250 26 224 
Mean 270.548 178.6538 281.2143 
SD 52.55068 28.0855 43.54626 
P value 
Unpaired t test 
0.0000 
 
By conventional criteria the association between the study groups and post 
prandial blood sugar levels among study subjects is considered to be 
statistically significant since p < 0.05.  
 
Statistical Significance 
This indicates that there is a true difference among groups and the 
difference is significant. . In simple terms, when studying the 
mucocutaneous lesions among diabetic patients, the post prandial blood 
sugar levels in good blood glucose control group is predominantly 
less(179.65±28.08 mg/dl) when compared to poor blood glucose control 
group(281.21±43.55). It is statistically significant with a p-value of 0.0000 
according to unpaired t-test. 
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Clinical Significance 
 
The average post prandial blood sugar levels in good blood glucose control 
group is meaningfully less than poor blood glucose control by 57.4% with a 
mean difference of 102.56 mg/dl between the groups.  This difference is 
true and significant and has not occurred by chance. 
 
Conclusion  
We conclude that there is meaningfully real reduction in post prandial blood 
glucose levels among good blood glucose control group  
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Duration of Diabetes 
 
Duration 
of 
Diabetes 
All % 
Good 
Control 
% 
Poor 
Control 
% 
≤ 2 years 41 16.4 4 15.38462 38 16.96429 
2 to 5 
years 
60 24 8 30.76923 52 23.21429 
5 to 10 
years 
99 39.6 10 38.46154 89 39.73214 
> 10 years 49 19.6 4 15.38462 45 20.08929 
Total 249 99.6 26 100 224 100 
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Duration of 
Diabetes 
All Good Control Poor Control 
N 249 26 224 
Mean 7.343373 6.403846 7.419643 
SD 4.688649 3.77894 4.793752 
P value 
Unpaired t test 
0.2166 
 
By conventional criteria the association between the study groups and 
duration of diabetes is considered to be not statistically significant since p > 
0.05. 
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Type of Diabetes 
 
 
Type of 
Diabetes 
All % 
Good 
Control 
% PoorControl % 
Type 1 
Diabetes 
25 10 9 34.61538 16 7.142857 
Type 2 
Diabetes 
225 90 17 65.38462 208 92.85714 
Total 250 100 26 100 224 100 
P value 
Chi squared Test 
0.00001 
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By conventional criteria the association between the study groups and type 
of diabetes  among study subjects is considered to be statistically significant 
since p < 0.05.  
Statistical Significance 
This indicates that there is a true difference among groups and the 
difference is significant. . In simple terms, when studying the 
mucocutaneous lesions among diabetic patients, type 2 diabetes patients in 
good blood glucose control group is predominantly lesswhen compared to 
poor blood glucose control group. It is statistically significant with a p-value 
of 0.00001 according to chi squared test. 
Clinical Significance 
The , the percentage of type 2 diabetes patients in good blood glucose 
control group is meaningfully less in good blood glucose control group than 
poor blood glucose control by 42% with a difference of 27.47 percentage 
points between the groups.  This difference is true and significant and has 
not occurred by chance. 
Conclusion  
We conclude that there is meaningfully real increase in , type 2 
diabetes patients among poor blood glucose control group  
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Type of Treatment 
 
Type of 
Treatment 
All % 
Good 
Contro
l 
% 
PoorContro
l 
% 
Oral Drugs 194 77.6 13 50 181 
80.8035
7 
Insulin 25 10 9 
34.6153
8 
16 
7.14285
7 
Oral Drugs 
and Insulin 
31 12.4 4 
15.3846
2 
27 
12.0535
7 
Total 250 100 26 100 224 100 
P value 
Chi squared Test 
0.00000 
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By conventional criteria the association between the study groups and type 
of treatment among study subjects is considered to be statistically 
significant since p < 0.05.  
 
Statistical Significance 
This indicates that there is a true difference among groups and the 
difference is significant. . In simple terms, when studying the 
mucocutaneous lesions among diabetic patients, the treatment with oral 
drugs given to patients in good blood glucose control group is 
predominantly less when compared to poor blood glucose control group. 
Similarly the treatment with insulin  given to patients in good blood glucose 
control group is predominantly high when compared to poor blood glucose 
control group It is statistically significant with a p-value of 0.00000 
according to chi squared test. 
 
Clinical Significance 
 
The percentage of patients on oral drugsin good blood glucose control group 
is meaningfully less in good blood glucose control group than poor blood 
glucose control by 1.61 times with a difference of 30.80 percentage points 
between the groups.   
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The percentage of patients on insulin in good blood glucose control group is 
meaningfully more than poor blood glucose control by 4.85 times with a 
difference of 27.47 percentage points between the groups.   
 
This difference is true and significant and has not occurred by chance. 
 
Conclusion  
We conclude that there is meaningfully real increase in patients with good 
blood glucose control when on insulin and meaningfully real increase in 
patients with poor blood glucose control when on oral drugs.  
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Cutaneous Lesions 
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Cutaneous 
Lesions 
All % 
Good 
Control 
% 
Poor 
Control 
% 
P value 
Chi 
squared 
Test 
Balanoposthitis 10 4 0 0 10 4.464286 0.271515 
Ulcer Foot 33 13.2 2 7.692308 31 13.83929 0.380754 
Gangrene 5 2 1 3.846154 4 1.785714 0.477487 
Neuropathic 
Ulcer 
26 10.4 2 7.692308 24 10.71429 0.632781 
Eczema 14 5.6 0 0 14 6.25 0.189513 
Intertrigo 13 5.2 0 0 13 5.803571 0.207084 
Xanthoma 2 0.8 1 3.846154 1 0.446429 0.065479 
Icthyosis 17 6.8 5 19.23077 12 5.357143 0.007816 
Vitiligo 3 1.2 0 0 3 1.339286 0.552733 
Acanthosis 11 4.4 1 3.846154 10 4.464286 0.884342 
Skin Tags 17 6.8 2 7.692308 15 6.696429 0.848577 
Dermapathy 6 2.4 1 3.846154 5 2.232143 0.610753 
Scleroderma 14 5.6 3 11.53846 11 4.910714 0.164129 
Keratosis 
Pilaris 
3 1.2 2 7.692308 1 0.446429 0.001319 
Dry Scaly 
Palms 
3 1.2 1 3.846154 2 0.892857 0.190495 
Pruritus 18 7.2 0 0 18 8.035714 0.133495 
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Cutaneous 
Lesions All Good Control PoorControl 
Absent 72 3 69 
Present 178 26 152 
Total 250 29 221 
P value 
Chi squared 
Test 
0.019581 
 
By conventional criteria the association between the study groups and 
cutaneous lesions among study subjects is considered to be statistically 
significant since p < 0.05.  
Statistical Significance 
This indicates that there is a true difference among groups and the 
difference is significant. . In simple terms, when studying the 
mucocutaneous lesions among diabetic patients, the prevalence of cutaneous 
lesions among patients  in good blood glucose control group is 
predominantly more when compared to poor blood glucose control group. It 
is statistically significant with a p-value of 0.019581 according to chi 
squared test. 
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Clinical Significance 
 
The prevalence of cutaneous lesions among patientsin good blood glucose 
control group is meaningfully more in good blood glucose control group 
than poor blood glucose control by 1.3 times with a difference of 20.88 
percentage points between the groups.   
This difference is true and significant and has not occurred by chance. 
 
Conclusion  
We conclude that there is meaningfully real increase in patients with 
cutaneous lesions among  good blood glucose control  when compared with 
poor blood glucose control.  
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Cutaneous Infections 
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Cutaneous 
Infections 
All % 
Good 
Control 
% 
Poor 
Control 
% 
P value 
Chi 
squared 
Test 
Candidiasis 13 5.2 0 0 10 4.464286 0.268165 
Carbuncle 3 1.2 0 0 3 1.339286 0.552733 
Furuncle 8 3.2 0 0 8 3.571429 0.327371 
Cellulitis 18 7.2 1 3.846154 17 7.589286 0.484594 
TineaCorporis 10 4 2 7.692308 8 3.571429 0.310107 
TineaPedis 10 4 2 7.692308 8 3.571429 0.310107 
Abscess 16 6.4 1 3.846154 15 6.696429 0.57406 
Onychomycosis 9 3.6 0 0 9 4.017857 0.297881 
Paronychia 10 4 0 0 10 4.464286 0.271515 
 
Cutaneous 
Infections All Good Control PoorControl 
Absent 155 26 129 
Present 95 3 92 
Total 250 29 221 
P value 
Chi squared 
Test 
0.001101 
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By conventional criteria the association between the study groups and 
cutaneous infections among study subjects is considered to be statistically 
significant since p < 0.05.  
Statistical Significance 
This indicates that there is a true difference among groups and the 
difference is significant. . In simple terms, when studying the 
mucocutaneous lesions among diabetic patients, the prevalence of cutaneous 
infections among patients in good blood glucose control group is 
predominantly less when compared to poor blood glucose control group. It 
is statistically significant with a p-value of 0.001101 according to chi 
squared test. 
Clinical Significance 
The prevalence of cutaneous infections among patients in good blood 
glucose control group is meaningfully less in good blood glucose control 
group than poor blood glucose control by 14.02 times with a difference of 
31.28 percentage points between the groups.   
This difference is true and significant and has not occurred by chance. 
 
Conclusion  
We conclude that there is meaningfully real decrease in patients with 
cutaneous infections among good blood glucose control  when compared 
with poor blood glucose control.  
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Age Distributions of Cutaneous Lesions 
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Age Distribution of 
Cutaneous Lesions 
≤ 20 
years 
21 to 40 
years 
41 to 
60 
years 
> 60 
years Total % 
BALANOPOSTHITIS 0 0 9 0 9 6 
ULCER FOOT 0 3 22 5 30 18 
GANGRENE 0 0 2 2 4 2 
NEUROPATHIC 
ULCER 0 0 15 7 22 13 
ECZEMA 0 2 5 2 9 6 
INTERTRIGO 0 0 8 2 10 6 
XANTHOMA 0 0 1 0 1 1 
ICTHYOSIS 4 8 2 2 16 10 
VITILIGO 0 1 1 0 2 1 
ACANTHOSIS 0 3 4 1 8 5 
SKIN TAG 0 4 5 3 12 7 
DERMOPATHY 0 2 2 1 5 3 
SCLEREDEMA 4 4 4 1 13 8 
KERATOSIS PILARIS 0 3 0 0 3 2 
DRY SCALY PALMS 1 2 0 0 3 2 
PRURITUS 0 2 11 3 16 10 
Total 163 100 
P value 
Chi squared Test 0.9820 
 
By conventional criteria the association between the age groups and 
distribution of cutaneous lesions is considered to be not statistically 
significant since p > 0.05. 
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Age Distribution of Cutaneous Infections 
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Age Distribution of 
Cutaneous 
Infections 
≤ 20 
years 
21 to 
40 
years 
41 to 
60 
years 
> 60 
years 
Total % 
VAGINAL 
CANDIDIASIS 
0 6 2 3 11 15 
CARBUNCLE 0 0 1 0 1 1 
FURUNCULOSIS 0 1 3 1 5 7 
CELLULITIS 0 2 11 3 16 22 
TINEA CORPORIS 0 3 1 2 6 8 
TINEA PEDIS 1 3 3 1 8 11 
ABSCESS 0 2 5 4 11 15 
ONYCHOMYCOSI
S 
0 1 6 0 7 9 
PARONYCHIA 0 1 6 2 9 12 
Total 74 100 
P value 
Chi squared Test 
0.4769 
 
By conventional criteria the association between the age groups and 
distribution of cutaneous infections is considered to be not statistically 
significant since p > 0.05. 
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Cutaneous Lesions and Duration of Diabetes 
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Duration of Diabetes 
and Cutaneous 
Lesions 
≤ 2 
years 
2 to 5 
years 
5 to 10 
years 
> 10 
years Total % 
BALANOPOSTHITIS 3 1 5 1 9 6 
ULCER FOOT 2 6 8 17 16 11 
GANGRENE 0 0 1 4 1 1 
NEUROPATHIC 
ULCER 0 1 11 14 12 8 
ECZEMA 2 7 5 0 14 10 
INTERTRIGO 1 4 5 3 10 7 
XANTHOMA 1 1 0 0 2 1 
ICTHYOSIS 1 2 13 1 16 11 
VITILIGO 0 2 1 0 3 2 
ACANTHOSIS 4 3 2 2 9 6 
SKIN TAG 6 5 4 2 15 10 
DERMOPATHY 1 3 1 1 5 3 
SCLEREDEMA 0 5 7 2 12 8 
KERATOSIS 
PILARIS 0 1 2 0 3 2 
DRY SCALY PALMS 0 1 2 0 3 2 
PRURITUS 4 6 5 3 15 10 
Tamil 145 100 
P value 
Chi squared Test 0.7766 
 
By conventional criteria the association between the duration of diabetes 
and distribution of cutaneous lesions is considered to be not statistically 
significant since p > 0.05. 
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Cutaneous Infections and Duration of Diabetes 
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Duration of 
Diabetes and 
Cutaneous 
Infections 
≤ 2 
years 
2 to 5 
years 
5 to 10 
years 
> 10 
years 
Total % 
VAGINAL 
CANDIDIASIS 
4 3 4 2 11 13 
CARBUNCLE 2 1 0 0 3 4 
FURUNCULOSIS 3 0 4 1 7 8 
CELLULITIS 5 3 8 2 16 19 
TINEA CORPORIS 4 5 1 0 10 12 
TINEA PEDIS 1 3 6 0 10 12 
ABSCESS 4 2 8 2 14 16 
ONYCHOMYCOSI
S 
0 3 4 2 7 8 
PARONYCHIA 1 3 3 3 7 8 
Total 85 100 
P value 
Chi squared Test 
0.0924 
 
By conventional criteria the association between the duration of diabetes 
and distribution of cutaneous infections is considered to be not statistically 
significant since p > 0.05. 
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Cutaneous Lesions and Glycemic Control 
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Glycemic Control 
and Cutaneous 
Lesions 
Good 
Control 
Poor 
control 
Total % 
BALANOPOSTHITIS 0 10 10 5 
ULCER FOOT 2 31 33 17 
GANGRENE 1 4 5 3 
NEUROPATHIC 
ULCER 
2 24 26 13 
ECZEMA 0 14 14 7 
INTERTRIGO 0 13 13 7 
XANTHOMA 1 1 2 1 
ICTHYOSIS 5 12 17 9 
VITILIGO 0 3 3 2 
ACANTHOSIS 1 10 11 6 
SKIN TAG 2 15 17 9 
DERMOPATHY 1 5 6 3 
SCLEREDEMA 3 11 14 7 
KERATOSIS 
PILARIS 
2 1 3 2 
DRY SCALY PALMS 1 2 3 2 
PRURITUS 0 18 18 9 
Total 195 100 
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Cutaneous Infections and Glycemic Control 
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Glycemic Control and 
Cutaneous Infections 
Good 
Control 
Poor 
control 
Total % 
VAGINAL 
CANDIDIASIS 
0 13 13 13 
CARBUNCLE 0 3 3 3 
FURUNCULOSIS 0 8 8 8 
CELLULITIS 1 17 18 19 
TINEA CORPORIS 2 8 10 10 
TINEA PEDIS 2 8 10 10 
ABSCESS 1 15 16 16 
ONYCHOMYCOSIS 0 9 9 9 
PARONYCHIA 0 10 10 10 
Total 97 100 
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Dermatological Conditions 
Type 1 
Diabetes 
Type 2 
Diabetes 
Total % 
BALANOPOSTHITIS 0 10 10 3.42 
VAGINAL CANDIDIASIS 0 13 13 4.45 
ULCER FOOT 0 33 33 11.30 
GANGRENE 0 5 5 1.71 
NEUROPATHIC ULCER 0 26 26 8.90 
ECZEMA 0 14 14 4.79 
HYDRADENITIS SUPPURATIVA 0 0 0 0.00 
INTERTRIGO 0 13 13 4.45 
CABUNCLE 0 3 3 1.03 
FURUNCULOSIS 0 8 8 2.74 
CELLULITIS 0 18 18 6.16 
XANTHOMA 0 2 2 0.68 
ICTHYOSIS 9 8 17 5.82 
VITILIGO 1 2 3 1.03 
ACANTHOSIS 0 11 11 3.77 
TINEA CORPORIS 0 10 10 3.42 
TINEA PEDIS 2 8 10 3.42 
ABSCESS 0 16 16 5.48 
ONYCHOMYCOSIS 0 9 9 3.08 
SKIN TAG 0 17 17 5.82 
DERMOPATHY 0 6 6 2.05 
SCLEREDEMA 7 7 14 4.79 
KERATOSIS PILARIS 3 0 3 1.03 
DRY SCALY PALMS 3 0 3 1.03 
PRURITUS 0 18 18 6.16 
PARONYCHIA 0 10 10 3.42 
Total 25 267 292 100 
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DISCUSSION 
Previous studies shows that example 
Kahana Et al screened 216 patients with skin tags and found to have overt 
Diabetes mellitus and impaired glucose tolerance test is 7.9% 
Thappa Et al found that 62% of patients with skin tags has diabetes. So 
these 2 studies state that these are markers for diabetes mellitus. 
Requena Et al found that clear cell porocarcinoma as a cutaneous marker of 
diabetes mellitus. Glycogen accumulation with in their cytoplasm results in 
clear cell appearance of neoplastic cells. 
Grandhe Et al found that AN is independent cutaneous marker of T2DM. 
There is also increased frequency of diabetic dermopathy, hairloss over legs, 
AN, syringoma, callosity, brittle nails, icthyosis, cutaneous amyloidosis. 
Mahajen Et al shows no statistical association between diabetic 
dermoangiopathy and diabetic retinopathy, neuropathy, hypertension. 
AN is present in 3% of the diabetics.Pruritus is present in 10 % of diabetics. 
Most common age group is 41-50 years. 
Frost Et al shows 33% had LJM in 335 type 1 diabetes mellitus. 
 In mutairi Et al most common age group is 40-60 years. AN is present in 
4.7% 
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Nigam and pande Et al shows 61% of diabetics had cutaneous dermatosis 
and 4.5% had pruritus. 
In bhat Et al duration of diabetes is upto 10 years. AN is present in 5.3% of 
Diabetics. 
In Ahmed Et al, AN is present in 2.8% of Diabetics. 
Shivanna Ragunatha Et al shows majority of patients have FBG < 130% and 
type 2 DM is 60%. Statistically significant difference between the patients 
with and without DM specific cutaneous disorders was noticed with 
reference to age and gender distribution, duration of DM and FBG. 
Signs of IR, acrochordan 26% , AN 5% , Fungal infection 13%, bacterial 
infection 6.8%, eruptive xanthoma 0.6%, diabetic foot 0.2%, diabetic bulla 
0.4%, diabetic dermopathy 0.2%, generalized granuloma annulare 0.2%, 
insulin reaction 6.2%, lipo dystrophy 14%. 
DuriyeDenizdermiseren Et al shows 750 patients have examined of these 
most common cutaneous skin manifestations are cutaneous infections 47%, 
xerosis 26%, inflammatory skin disease 20%. Patients with HbA1c greater 
than or equal to 8 mmol had more skin disorders than HbA1C of less than 8 
mmol. 
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SUMMARY AND CONCLUSION 
Diabetic Patients who are attending Diabetology OPD, Dermatology OPD 
& ward, Medicine OPD & ward were screened for dermatological 
manifestations. Patients height, weight, BMI, Blood pressure was measured. 
History of Alcohol & Smoking was obtained. Blood investigations (FBS, 
PPBS, RFT) were done. History regarding Duration of diabetes and 
associated medical illness were also obtained. Treatment details regarding 
DM were also recorded. Dermatologist opinion was obtained. Patient’s 
muco cutaneous manifestations were treated according to guidelines. 
In this study, in Type 2 DM , most of muco cutaneous manifestations( Eg. 
Cellulitis, vaginal candidiasis, abscess, paronychia ,scleredema, eczema, 
intertrigo) are associated with poor glycemic status.  
Cutaneous infections are associated with poor glucose control. 
Neuropathic ulcer, ulcer foot, Abscess and cellulitis are associated with long 
duration of diabetes (>10years duration). 
In newly detected DM, common manifestations are furunculosis, pruritus, 
abscess,skin tag, tinea corporis, acanthosis, vaginal candidiasis, 
balanoposthitis. 
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Most common age group for mucocutaneous manifestations are 41-60years. 
Most of the mucocutaneous manifestations commonly occur in 5-10 yrs of 
duration of diabetes.  
In Type1DM, distribution of mucocutaneous manifestations are 
Icthyosis     36% 
Keratosis pilaris    12% 
Dry scaly palms    12% 
Vitiligo     4% 
Sceleroderma like changes  28% 
Tinea pedis     8% 
In Type 2 DM most common mucocutaneous manifestations are ulcer foot 
(11.3%) 
Demographic profile number percentage 
Total patients 250 100 
Type 1- male 10 4 
Type 1- female 15 6 
Type 2 - male 100 40 
Type 2 – female 125 50 
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Type 1 DM 
(Uncontrolled)  
22 8.8 
Type 1 DM  
(controlled)  
3 1.2 
Type 2 DM 
(Uncontrolled)  
202 80.8 
Type 2 DM 
(Controlled)  
23 9.2 
Mean age - type 1 24+/-4  
Mean age - type 2 52+/-7  
Mean Duration in years 
- type 1 
7 +/- 1  
Mean Duration in years 
- type 2 
8+/- 5  
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PROFORMA 
Name: 
Age/sex: 
Occupation:                                                                           DOB: 
Address with contact no: 
IP NO/OP NO: 
Type of diabetes: 
Treatment history: 
History of Mucocutaneous manifestations: 
Family history of skin manifestations: 
FBS:                                            PPBS:                                        HIV: 
B.Urea                                         S.Creatinine 
Height:                                        Weight:                                      BMI: 
PAST HISTORY 
Hypertension:                              CAD:                                         Epilepsy: 
Dyslipidemia:                               CKD:                                        CVA: 
EXAMINATION: 
Pallor:                                             Icterus:                                        
Pedal edema: 
PR:                                              BP: 
CVS: 
RS: 
P/A: 
CNS: 
MUCOCUTANEOUS MANIFESTATIONS 
CUTANEOUS INFECTIONS 
Candidiasis 
Intertrigo 
Folliculitis 
Furunculosis 
Carbuncle 
Cellulitis 
Malignant otitis externa 
Paronychia 
Onychomycosis 
Abscess 
Eczema 
Tinea pedis 
Tinea Corporis 
Gangrene 
Ulcer foot 
Vaginal Candidiasis 
Balanoposthitis 
NEUROLOGIC LESIONS 
Neuropathic ulcers 
DISORDERS OF COLLAGEN 
Necrobiosis lipoidica 
Granuloma annulare 
Scleredema diabeticorum 
Scleroderma like change of the hand 
Waxy skin 
METABOLIC DISEASE 
Xanthomatosis 
Generalized pruritus 
OTHERS 
Acquired icthyosis      Diabetic dermopathy 
Diabetic bullae     Vitiligo 
Acanthosis nigricans  Xanthoma   Skin Tag 
MASTER CHART 
Serial 
No. AGE 
SEX 
Ht 
in 
mt 
Wt 
in 
kgs BMI alcohol smoking BP FBS PPBS 
duration 
of 
diabetes skin findings 
type 
of 
DM treatment 
1 60 F 1.7 65 22.4 NO NO 120/80 170 278 5 ulcer foot t2 o 
2 57 f 1.6 85 32.0 NO NO 150/90 320 450 10 cellulitis, pruritus t2 o+i 
3 43 f 1.40 55 28.1 NO NO 120/70 98 196 1 skin tags t2 o 
4 60 f 1.55 60 25.0 NO NO 130/90 126 224 2 acanthosis t2 o 
5 48 f 1.7 65 27.1 NO NO 130/80 152 252 5 ulcer foot,paronychia t2 o 
6 44 f 1.7 55 26.2 NO NO 140/90 178 300 5 vitiligo t2 o 
7 57 f 1.45 55 26.2 NO NO 150/80 112 198 5 acanthosis t2 o 
8 50 f 1.55 60 25.0 NO NO 150/90 106 186 5 skin tag t2 o 
9 53 f 1.45 55 26.2 NO NO 130/90 145 300 3 ulcer foot t2 o 
10 65 f 1.53 55 23.5 NO NO 120/80 156 256 15 dermopathy t2 o+i 
11 65 f 1.45 70 33.3 NO NO 140/90 102 196 15 icthyosis t2 o+i 
12 56 
f 
1.6 63 24.6 NO NO 130/80 238 357 
 newly 
detected cellulitis,pruritus t2 o 
13 47 
f 
1.55 60 25.0 NO NO 130/76 191 222 
6 
months tinea pedis t2 o 
14 35 
f 
1.6 84 32.8 NO NO 150/80 119 185 
6 
months ulcer foot t2 o 
15 56 f 1.55 65 27.1 NO NO 130/70 99 198 12 Scleredema t2 o+i 
16 60 f 1.55 60 25.0 NO NO 120/70 180 360 3 cellulitis,pruritus t2 o 
17 70 
f 
1.6 50 19.5 NO NO 120/70 126 226 
 newly 
detected furuncle,pruritus t2 o 
18 65 f 1.6 56 21.9 NO NO 140/90 198 302 3 tinea corporis t2 o 
19 46 
f 
1.58 60 24.0 NO NO 130/80 218 302 
2 
months Abscess t2 o 
20 42 
f 
1.4 45 23.0 NO NO 150/90 250 398 10 
vaginal 
candidiasis,pruritus t2 O+I 
21 54 f 1.5 60 26.7 NO NO 120/70 250 350 6 onychomycosis t2 o 
22 55 f 1.6 70 27.3 NO NO 130/80 240 340 10 Scleredema,pruritus t2 o 
23 36 f 1.6 70 27.3 NO NO 150/70 265 365 2 skin tag, herpes zoster t2 o 
24 58 f 1.55 60 25.0 NO NO 130/60 211 312 30 Intertrigo t2 O+I 
25 68 f 1.6 60 23.4 NO NO 140/90 413 450 1 tinea corporis,pruritus t2 o 
26 64 
f 
1.55 55 22.9 NO NO 130/80 218 312 
2 
months Eczema t2 o 
27 74 f 1.6 60 23.4 NO NO 120/70 82 98 10 tinea pedis t2 o 
28 52 f 1.55 50 20.8 NO NO 140/80 168 268 5 vaginal candidiasis t2 o 
29 55 
f 
1.55 50 20.8 NO NO 120/70 236 326 7 
intertrigo, 
paronychia,pruritus t2 o 
30 70 f 1.6 65 25.4 NO NO 130/80 90 105 5 neuropathic ulcer t2 o 
31 70 f 1.5 50 22.2 NO NO 120/70 90 140 15 ulcer foot,gangrene t2 o+i 
32 40 
F 
1.45 60 28.6 NO NO 130/70 98 156 
newly 
detected Abscess t2 o 
33 65 
F 
1.5 50 22.2 NO NO 130/80 126 246 5 
vaginal 
candidiasis,pruritus t2 o 
34 40 F 1.6 80 31.2 NO NO 110/70 85 160 1.5 tinea corporis t2 o 
35 45 
F 
1.52 69 29.9 NO NO 140/90 136 245 
newly 
detected tinea corporis t2 o 
36 63 F 1.57 55 22.3 NO NO 150/90 250 326 15 ulcer foot t2 o+i 
37 32 F 1.6 58 22.7 NO NO 120/80 116 240 6 vaginal candidiasis t2 o 
38 42 
F 
1.63 68 25.6 NO NO 120/80 126 220 5 
tinea 
corporis,paronychia t2 o 
39 46 F 1.54 56 23.6 NO NO 130/90 110 198 3 Dermopathy t2 o 
40 54 F 1.62 61 23.3 NO NO 140/90 106 176 11 neuropathic ulcer t2 o+i 
41 35 
F 
1.7 70 24.2 NO NO 120/80 138 240 
newly 
detected Furuncle,skin tags t2 o 
42 45 F 1.54 51 21.5 NO NO 120/80 135 234 10 ulcer foot,gangrene t2 o 
43 61 F 1.65 75 27.6 NO NO 140/80 140 280 15 neuropathic ulcer t2 o+i 
44 42 F 1.7 66 22.8 NO NO 150/90 230 380 5 Eczema t2 o 
45 35 
F 
1.68 58 20.6 NO NO 120/80 132 240 
newly 
detected Acanthosis t2 o 
46 46 F 1.55 52 21.7 NO NO 140/80 125 210 7 skin tags/acanthosis t2 o 
47 45 F 1.58 59 23.6 NO NO 160/100 140 260 8 intertrigo t2 o 
48 36 F 1.6 57 22.3 NO NO 140/80 130 280 2 icthyosis t2 o 
49 38 F 1.51 59 25.9 NO NO 130/90 112 190 8 icthyosis t2 o 
50 63 F 1.52 55 23.8 NO NO 130/80 156 302 15 ulcer foot, gangrene t2 o+i 
51 62 F 1.59 58 23.0 NO NO 130/80 115 202 19 neuropathic ulcer t2 o+i 
52 53 F 1.59 53 21.0 NO NO 120/84 130 260 8 Scleredema t2 o 
53 36 F 1.52 50 21.7 NO NO 120/80 145 260 4 vaginal candidiasis t2 o 
54 47 F 1.42 49 24.3 NO NO 140/90 230 390 7 eczema,pruritus t2 o 
55 45 
F 
1.6 59 23.1 NO NO 130/80 150 236 
newly 
detected acanthosis t2 o 
56 55 F 1.57 53 21.5 NO NO 120/80 190 420 12 ulcer foot t2 o 
57 42 F 1.61 60 23.2 NO NO 140/84 140 260 2 tinea pedis t2 o 
58 57 F 1.54 48 20.2 NO NO 120/80 140 280 8 neuropathic ulcer t2 o 
59 61 F 1.53 55 23.5 NO NO 140/80 130 270 17 intertrigo, paronychia t2 o+i 
60 60 F 1.52 66 28.6 NO NO 140/80 190 320 10 ulcer foot t2 o 
61 40 
F 
1.51 65 28.5 NO NO 120/88 156 302 
newly 
detected vaginal candidiasis t2 o 
62 37 
F 
1.57 70 28.4 NO NO 120/80 140 280 8 
tinea 
corporis,paronychia t2 o 
63 59 F 1.56 69 28.4 NO NO 150/90 113 186 9 Scleredema t2 o 
64 58 F 1.6 77 30.1 NO NO 160/100 155 285 16 ulcer foot,gangrene t2 o 
65 36 F 1.62 65 24.8 NO NO 120/80 113 202 3 dermopathy t2 o 
66 52 F 1.55 58 24.2 NO NO 150/70 160 280 9 vaginal candidiasis t2 o 
67 55 F 1.62 75 28.6 NO NO 140/80 140 270 16 neuropathic ulcer t2 o 
68 66 F 1.57 62 25.2 NO NO 140/90 128 302 18 ulcer foot t2 O+I 
69 52 F 1.51 64 28.1 NO NO 120/84 160 237 14 ulcer foot,gangrene t2 o 
70 51 F 1.58 68 27.2 NO NO 140/80 139 218 9 skin tags/acanthosis t2 o 
71 37 
F 
1.51 70 30.7 NO NO 120/84 147 232 
newly 
detected skin tags t2 o 
72 48 F 1.62 62 23.6 NO NO 120/80 132 260 7 onychomycosis t2 o 
73 38 F 1.5 69 30.7 NO NO 120/86 240 420 5 eczema,pruritus t2 o 
74 58 F 1.59 72 28.5 NO NO 140/80 189 270 16 ulcer foot t2 o 
75 61 F 1.53 68 29.1 NO NO 140/80 200 290 17 abscess, skin tags t2 o 
76 48 F 1.57 62 25.2 NO NO 120/86 178 299 2 dermopathy t2 o 
77 37 
F 
1.5 58 25.8 NO NO 120/80 168 257 
newly 
detected 
vaginal 
candidiasis,pruritus t2 o 
78 38 F 1.58 51 20.4 NO NO 140/88 145 257 6 tinea pedis t2 o 
79 47 F 1.59 60 23.7 NO NO 120/80 170 287 3 tinea corporis t2 o 
80 51 F 1.6 56 21.9 NO NO 160/100 211 290 10 neuropathic ulcer t2 o 
81 55 F 1.57 72 29.2 NO NO 120/80 132 230 14 onychomycosis t2 o+i 
82 59 F 1.6 59 23.1 NO NO 130/90 200 410 13 ulcer foot,paronychia t2 o 
83 39 F 1.55 60 25.0 NO NO 120/80 189 270 5 tinea pedis t2 o 
84 31 
F 
1.59 58 23.0 NO NO 120/80 200 290 
newly 
detected skin tags, acanthosis t2 o 
85 41 F 1.59 55 21.8 NO NO 120/88 178 280 4 skin tags, acanthosis t2 o 
86 50 F 1.51 68 29.8 NO NO 140/90 145 240 10 tinea pedis t2 o 
87 40 F 1.52 74 32.0 NO NO 120/80 179 256 5 acanthosis t2 o 
88 60 F 1.6 76 29.7 NO NO 150/90 150 268 17 neuropathic ulcer t2 o+i 
89 38 
F 
1.53 65 27.8 NO NO 120/80 156 228 
newly 
detected cellulitis t2 o 
90 49 F 1.52 70 30.3 NO NO 140/80 146 260 8 intertrigo, paronychia t2 o 
91 31 
F 
1.68 75 26.6 NO NO 130/90 156 279 
newly 
detected tinea corporis t2 o 
92 61 F 1.63 65 24.5 NO NO 120/80 187 266 13 vaginal candidiasis t2 o+i 
93 39 F 1.5 60 26.7 NO NO 120/80 178 269 5 eczema t2 o 
94 48 F 1.52 57 24.7 NO NO 120/80 189 292 4 intertrigo, paronychia t2 o 
95 60 F 1.62 78 29.7 NO NO 140/86 179 299 19 neuropathic ulcer t2 o 
96 39 F 1.54 69 29.1 NO NO 130/88 168 294 6 icthyosis t2 o 
97 61 F 1.52 54 23.4 NO NO 140/90 156 289 17 skin tags, acanthosis t2 o+i 
98 41 F 1.61 69 26.6 NO NO 120/80 193 276 2 vaginal candidiasis t2 o 
99 38 F 1.52 57 24.7 NO NO 120/84 147 269 4 onychomycosis t2 o 
100 47 F 1.51 70 30.7 NO NO 120/80 189 299 2 eczema t2 o 
101 61 F 1.61 57 22.0 NO NO 140/84 129 279 18 intertrigo, paronychia t2 o+i 
102 33 F 1.55 60 25.0 NO NO 120/86 138 280 2 cellulitis t2 o 
103 55 F 1.59 58 23.0 NO NO 140/90 169 289 9 dermopathy t2 o 
104 37 F 1.66 68 24.7 NO NO 120/80 178 289 3 abscess t2 o 
105 61 F 1.6 57 22.3 NO NO 150/100 189 290 11 ulcer foot t2 o 
106 39 
F 
1.62 72 27.4 NO NO 120/86 167 277 
newly 
detected vaginal candidiasis t2 o 
107 42 
F 
1.55 65 27.1 NO NO 120/80 180 298 
newly 
detected abscess t2 o 
108 38 
F 
1.53 67 28.6 NO NO 120/84 170 289 
newly 
detected abscess t2 o 
109 64 F 1.6 52 20.3 NO NO 120/80 189 268 10 neuropathic ulcer t2 o 
110 59 F 1.5 69 30.7 NO NO 140/86 178 270 18 ulcer foot t2 O+I 
111 49 F 1.54 55 23.2 NO NO 140/80 156 287 5 skin tags t2 o 
112 57 F 1.6 75 29.3 NO NO 160/100 157 298 14 acanthosis t2 O+I 
113 39 F 1.58 64 25.6 NO NO 120/80 145 270 3 Scleredema t2 o 
114 55 F 1.59 77 30.5 NO NO 140/80 167 299 10 Furuncle t2 o 
115 49 F 1.58 79 31.7 NO NO 120/84 189 301 5 Cellulitis t2 o 
116 60 F 1.61 79 30.5 NO NO 140/88 167 289 17 ulcer foot t2 O+I 
117 47 F 1.51 58 25.4 NO NO 120/80 150 268 8 skin tags t2 o 
118 38 F 1.6 76 29.7 NO NO 120/80 156 228 4 dermopathy t2 o 
119 65 F 1.52 79 34.2 NO NO 160/100 160 260 14 vaginal candidiasis t2 o+i 
120 49 F 1.55 78 32.5 NO NO 140/80 149 279   cellulitis t2 o 
121 41 
F 
1.51 75 32.9 NO NO 120/84 187 280 
newly 
detected Furuncle t2 o 
122 62 F 1.63 88 33.1 NO NO 130/90 178 269 18 neuropathic ulcer t2 o 
123 53 F 1.59 77 30.5 NO NO 120/80 189 292 13 Furuncle t2 o 
124 49 F 1.6 68 26.6 NO NO 130/84 179 299 10 Cellulitis t2 o 
125 40 F 1.57 53 21.5 NO NO 120/80 168 300 9 vaginal candidiasis t2 o 
126 42 m 1.68 70 24.8 YES YES 130/70 140 230 10 Eczema t2 o 
127 56 m 1.72 75 25.4 YES YES 110/70 156 220 12 ulcer foot t2 o 
128 43 m 1.66 77 28.0 NO YES 130/80 136 245 15 neuropathic ulcer t2 o 
129 44 
m 
1.69 70 24.5 NO NO 124/60 250 326 
10 
months balanoposthitis t2 o 
130 58 m 1.63 65 24.5 NO NO 150/100 150 275 7 Furuncle t2 o 
131 52 m 1.75 80 26.1 YES NO 140/90 126 226 8 tinea pedis t2 o 
132 51 m 1.55 75 31.2 NO NO 160/100 142 282 5 Eczema t2 o 
133 50 m 1.77 68 21.7 YES YES 130/80 232 322 4 ulcer foot t2 o 
134 48 m 1.68 76 26.9 NO NO 120/70 155 260 6 Abscess t2 o 
135 42 m 1.65 75 27.6 NO YES 120/70 145 280 3 onychomycosis t2 o 
136 53 
m 
1.7 79 27.3 NO NO 130/90 190 270 
newly 
detected balanoposthitis t2 o 
137 40 m 1.64 70 26.0 YES YES 140/70 186 276 10 ulcer foot t2 o 
138 55 m 1.59 72 28.5 NO YES 150/90 143 283 6 neuropathic ulcer t2 o 
139 44 m 1.63 65 24.5 YES YES 140/90 202 402 4 Icthyosis t2 o 
140 59 m 1.75 70 22.9 YES YES 130/90 178 302 12 balanoposthitis t2 o 
141 60 
m 
1.7 65 22.5 YES YES 120/90 162 280 
7 
months neuropathic ulcer t2 o 
142 43 m 1.65 66 24.3 NO NO 110/80 156 276 5 Scleredema t2 o 
143 49 m 1.57 68 27.6 NO NO 170/100 180 302 8 Abscess t2 o 
144 54 m 1.67 70 25.1 NO NO 150/90 136 246 6 balanoposthitis t2 o 
145 50 m 1.74 74 24.5 NO YES 140/90 128 220 10 neuropathic ulcer t2 o 
146 51 
m 
1.64 78 29.0 NO YES 130/80 126 280 
5 
months ulcer foot t2 o 
147 44 m 1.68 76 26.9 NO NO 130/80 146 300 9 Furuncle t2 o 
148 56 m 1.7 80 27.7 NO NO 120/84 136 276 10 Abscess t2 o 
149 55 
m 
1.75 78 25.5 NO NO 140/90 140 270 
7 
months balanoposthitis t2 o 
150 41 m 1.72 68 23.0 NO YES 140/80 190 320 11 neuropathic ulcer t2 o 
151 59 
m 
1.7 65 22.5 NO NO 130/80 163 297 
newly 
detected intertrigo, paronychia t2 o 
152 52 m 1.65 66 24.3 NO YES 120/70 165 276 8 ulcer foot t2 o 
153 51 m 1.6 63 24.6 YES YES 120/80 160 296 5 balanoposthitis t2 o 
154 43 m 1.72 62 21.0 NO NO 130/90 140 280 8 Abscess t2 o 
155 50 m 1.68 76 26.9 NO YES 130/80 126 254 8 neuropathic ulcer t2 o 
156 59 m 1.6 64 25.0 NO YES 120/90 158 278 4 intertrigo, paronychia t2 o 
157 43 m 1.74 70 23.1 NO NO 120/80 152 290 8 Cellulitis t2 o 
158 48 m 1.7 73 25.3 NO NO 150/100 138 240 6 Eczema t2 o 
159 56 m 1.6 65 25.4 NO YES 160/90 129 260 5 ulcer foot t2 o 
160 51 m 1.65 75 27.6 YES YES 130/80 126 320 4 skin tag t2 o 
161 45 m 1.68 69 24.5 YES YES 160/70 180 310 10 Cellulitis t2 o 
162 60 m 1.63 80 30.1 NO NO 160/80 184 340 12 ulcer foot t2 o 
163 55 m 1.73 76 25.4 YES YES 130/90 188 360 13 onychomycosis,pruritus t2 o 
164 58 m 1.62 78 29.7 YES YES 120/80 143 283 6 neuropathic ulcer t2 o 
165 56 m 1.64 74 27.5 NO NO 120/80 146 260 2 xanthoma t2 o 
166 52 m 1.65 75 27.6 NO NO 130/80 125 226 1 balanoposthitis t2 o 
167 48 m 1.63 73 27.5 NO NO 140/90 170 290 5 Eczema t2 o 
168 50 m 1.6 72 28.1 NO NO 150/90 180 300 4 abscess,pruritus t2 o 
169 52 m 1.58 71 28.5 NO NO 150/70 129 290 6 balanoposthitis t2 o 
170 62 m 1.78 70 22.1 NO NO 126/80 149 289 7 Cellulitis t2 o 
171 65 m 1.75 68 22.2 NO NO 110/80 202 315 15 Abscess t2 o 
172 65 m 1.74 80 26.4 YES YES 120/70 190 340 12 neuropathic ulcer t2 o 
173 60 m 1.72 75 25.4 YES YES 130/90 140 260 13 ulcer foot t2 o 
174 62 m 1.68 75 26.6 YES YES 140/90 180 270 10 neuropathic ulcer t2 o 
175 58 
m 
1.6 73 28.5 YES YES 150/100 180 260 
8 
months ulcer foot t2 o 
176 45 
m 
1.61 65 25.1 NO NO 120/80 130 280 
newly 
detected Abscess t2 o 
177 43 m 1.68 67 23.7 NO YES 130/70 140 270 10 neuropathic ulcer t2 o 
178 56 m 1.7 79 27.3 YES YES 120/90 150 259 12 ulcer foot t2 o 
179 67 m 1.69 75 26.3 NO NO 140/80 142 302 9 abscess, skin tags t2 o 
180 64 m 1.64 68 25.3 NO NO 136/78 162 320 6 Cellulitis t2 o 
181 54 m 1.72 79 26.7 NO NO 110/70 136 245 3 tinea corporis t2 o 
182 45 m 1.76 80 25.8 YES YES 136/80 156 298 12 neuropathic  ulcer t2 o 
183 58 m 1.67 70 25.1 NO NO 120/80 126 238 2 balanoposthitis t2 o 
184 46 m 1.75 77 25.2 NO NO 150/100 236 286 7 Furuncle t2 o 
185 48 m 1.63 72 27.1 NO NO 140/90 280 340 6 Cellulitis t2 o 
186 49 m 1.72 79 26.7 NO NO 160/90 124 224 8 Icthyosis t2 o 
187 60 m 1.65 69 25.4 YES YES 146/78 234 320 10 ulcer foot t2 o 
188 58 m 1.72 74 25.0 NO NO 110/80 132 230 9 balanoposthitis t2 o 
189 57 m 1.74 76 25.1 NO NO 120/90 142 265 5 Eczema t2 o 
190 45 m 1.78 77 24.3 NO NO 130/90 213 289 4 carbuncle t2 o 
191 42 m 1.8 80 24.7 NO NO 120/80 215 321 6 Intertrigo t2 o 
192 47 m 1.69 69 24.2 NO YES 140/80 221 312 10 neuropathic ulcer t2 o+i 
193 59 m 1.63 68 25.6 YES NO 150/90 245 333 13 cellulitis,pruritus t2 o+i 
194 56 m 1.71 70 23.9 NO NO 160/90 276 343 5 intertrigo,pruritus t2 o 
195 48 
m 
1.66 76 27.6 NO YES 150/80 265 354 11 
neuropathic 
ulcer,pruritus t2 O+I 
196 47 m 1.75 83 27.1 NO NO 126/90 143 232 1 carbuncle t2 o 
197 42 m 1.62 72 27.4 NO YES 130/70 165 254 15 ulcer foot t2 o+i 
198 60 m 1.78 78 24.6 YES YES 150/90 176 264 13 neuropathic ulcer t2 o+i 
199 61 m 1.72 76 25.7 NO NO 140/80 189 276 5 Eczema t2 o 
200 49 m 1.69 80 28.0 YES YES 130/70 187 278 11 neuropathic ulcer t2 o+i 
201 65 m 1.78 82 25.9 YES YES 140/90 165 276 5 Scleredema t2 o 
202 53 m 1.74 79 26.1 NO NO 160/90 132 245 4 skin tags t2 o 
203 44 m 1.68 78 27.6 NO NO 140/78 143 265 3 Intertrigo t2 o 
204 47 m 1.65 76 27.9 NO NO 110/80 176 256 8 onychomycosis t2 o 
205 56 m 1.76 75 24.2 NO NO 120/70 134 254 8 Vitiligo t2 o 
206 48 m 1.75 80 26.1 NO NO 130/70 123 224 7 Intertrigo t2 o 
207 59 m 1.78 76 24.0 NO YES 140/90 156 246 10 ulcer foot t2 o+i 
208 60 m 1.68 77 27.3 NO YES 150/80 176 254 10 neuropathic ulcer t2 o+i 
209 57 m 1.62 70 26.7 NO NO 112/70 145 265 8 Icthyosis t2 o 
210 58 m 1.73 76 25.4 NO NO 114/60 232 280 2 carbuncle t2 o 
211 44 m 1.69 80 28.0 NO NO 124/80 200 280 1 abscess, skin tags t2 o 
212 48 m 1.78 80 25.3 NO NO 148/80 198 270 5 tinea pedis t2 o 
213 59 m 1.72 70 23.7 NO NO 150/80 178 260 6 onychomycosis t2 o 
214 61 m 1.66 80 29.0 NO NO 146/90 167 270 6 Abscess t2 o 
215 64 m 1.64 82 30.5 NO NO 150/80 154 232 8 Cellulitis t2 o 
216 56 m 1.62 83 31.6 NO NO 134/80 132 198 2 Cellulitis t2 o 
217 41 m 1.65 70 25.7 NO NO 130/70 155 262 10 Eczema t2 o 
218 61 m 1.68 75 26.6 NO NO 120/80 143 263 5 Icthyosis t2 O 
219 44 m 1.72 78 26.4 NO NO 140/80 148 196 4 xanthoma t2 O 
220 48 m 1.68 73 25.9 YES YES 150/90 134 200 5 tinea corporis t2 O 
221 55 m 1.72 76 25.7 NO NO 120/80 150 250 2 Cellulitis t2 O 
222 43 m 1.8 80 24.7 NO NO 150/90 132 342 6 Abscess t2 O 
223 56 m 1.76 67 21.6 NO NO 140/70 176 266 7 Eczema t2 O 
224 57 m 1.76 76 24.5 NO NO 150/80 143 270 6 Abscess t2 O 
225 48 m 1.64 79 29.4 NO YES 116/76 123 260 4 Cellulitis t2 O 
226 19 f 1.6 81 19.5 NO NO 110/70 167 320 3 tinea pedis t1 I 
227 20 f 1.58 54 21.6 NO NO 112/80 155 240 7 dry scaly palms t1 I 
228 30 f 1.48 50 22.8 NO NO 110/60 177 160 10 Icthyosis t1 i 
229 29 f 1.52 51 22.1 NO NO 120/70 166 268 9 keratosis pilaris t1 i 
230 18 f 1.62 55 21.0 NO NO 110/80 161 251 7 Icthyosis t1 i 
231 21 f 1.58 52 20.8 NO NO 120/70 132 251 4 Vitiligo t1 i 
232 20 
f 
1.6 50 19.5 NO NO 130/70 101 196 5 
Scleroderma like 
changes t1 i 
233 20 f 1.65 50 18.4 NO NO 132/60 92 176 6 icthyosis t1 i 
234 28 f 1.54 50 21.1 NO NO 130/70 96 185 6 tinea pedis t1 i 
235 25 f 1.62 58 22.1 NO NO 120/74 152 250 5 dry scaly palms t1 i 
236 30 
f 
1.65 55 20.2 NO NO 120/70 104 184 8 
scleroderma like 
changes t1 i 
237 22 f 1.5 46 20.4 NO NO 120/80 110 198 4 keratosis pilaris t1 i 
238 19 
f 
1.55 52 21.6 NO NO 130/90 132 252 9 
scleroderma like 
changes t1 i 
239 25 f 1.6 48 18.7 NO NO 120/70 106 186 7 icthyosis t1 i 
240 16 
f 
1.55 48 20.0 NO NO 120/80 300 420 8 
scleroderma like 
changes t1 i 
241 26 m 1.7 65 22.5 NO NO 100/60 140 240 8 icthyosis t1 i 
242 25 m 1.65 70 25.7 NO NO 120/70 120 190 7 keratosis pilaris t1 i 
243 24 m 1.7 68 23.5 NO NO 130/70 160 270 10 icthyosis t1 i 
244 18 
m 
1.74 68 22.5 NO NO 180/50 132 232 3 
scleroderma like 
changes t1 i 
245 26 m 1.75 65 21.2 NO NO 110/70 118 198 6 dry scaly palms t1 i 
246 30 m 1.68 65 23.0 YES NO 130/80 152 262 9 icthyosis t1 i 
247 29 
m 
1.6 60 23.4 NO NO 130/70 143 263 9 
scleroderma like 
changes t1 i 
248 20 m 1.66 62 22.5 NO NO 126/70 112 196 7 icthyosis t1 i 
249 20 m 1.7 60 20.8 NO NO 128/70 108 158 8 icthyosis t1 i 
250 32 
m 
1.68 60 21.3 YES NO 110/70 150 250 12 
scleroderma like 
changes t1 i 
 
 
  
 
  
 
  
 
 
